# Appendix — Contact Lens Manufacturers Ass'n v. Food & Drug Administration

> Briefs, arguments, decisions, and more.

URL: https://www.frixlaw.com/law-library/documents/brief%3Amicro_IA40385018_1180%3A2

## Record

- **Collection:** Supreme Court brief
- **Document type:** Appendix
- **Published:** January 1, 1986
- **Citation:** 474 U.S. 1062

## Text

85-980 ~~ | ccs we

No.

vo | Supreme Court, us.
7):

a
oy
tr
os:

IN THE

Supreme Court of the United States

OctoBerR TERM, 1985

Contact LENS MANUFACTURERS ASSOCIATION,
Petitioner,
Vv.

Foop AND Drua ADMINISTRATION OF THE DEPARTMENT
OF HEALTH AND HuMAN SERVICES,

Respondent.

On Petition for Writ of Certiorari to the United States
Court of Appeals for the District of Columbia Circuit

APPENDIX TO
PETITION FOR WRIT OF CERTIORARI

DANIEL J. MANELLI
Counsel of Record

Epwarp A. SCALLET

THOMPSON & MITCHELL

1120 Vermont Avenue, N.W.
Suite 1000

Washington, D.C. 20005
(202) 857-0350

Attorneys for
Contact Lens Manufacturers
Association

ee sar eR UA EL CT ET TELA
PRESS OF BYRON S. ADAMS, WASHINGTON, D.C. (202) 347-8203

(i)
TABLE OF CONTENTS
Aprenpix A Page

July 9, 1985 Judgment of the United States Court
of Appeals for the District of Columbia Circuit .. la

Appenpix B

July 9, 1985 Opinion of the United States Court
of Appeals for the District of Columbia Circuit .. 2a

Appenpix C

September 10, 1985 Order of the United States
Court of Appeals for the District of Columbia
Circuit Denying Petition for Rehearing ....... 25a

Aprenpix D

Department of Health and Human Services, Food
and Drug Administration, 21 CFR 886 [Docket
No. 82N-0180], Reclassification of Daily Wear
Spherical Contact Lenses Consisting of Rigid Gas
Permeable Plastic Materials, Withdrawal of Pro-
OU ME PEL aida Cheese ck cub nen ecibnee snes ce 26a

Appenpix E

Department of Health and Human Services, Food
and Drug Administration, 21 CFR 886 [Docket
No. 82N-0180], Proposed Reclassification of Daily
Wear Spherical Contact Lenses Consisting of
Rigid Gas Permeable Plastic Materials ........ 106a

Appenpix F

Department of Health and Human Services, Food
and Drug Administration, 21 CFR 886 [Docket
No. 82N-0180], Notice of Intent: Reclassification
of Daily Wear Spherical Contact Lenses Con-
sisting Principally of Hydroxyethylmethacrylate
(HEMA) or Rigid Plastic Materials ........... 145a

(ii)
Taste or Corrents continued

Appenpix G Page

Department of Health and Human Services, Food
and Drug Administration, 21 CFR 886 [Docket
No. 82N-0180], Proposed Reclassification of Daily
Wear Spherical Contact Lenses Consisting of
Rigid Gas Permeable Plastic Materials; Reopen-
ing of Comment Period; Advance Notice of Public

SUES Gvcc cn cou ccccupnceeccteahecesuaswenues 149a
Apprenpix H

Statutes and Regulations Involved ............. 156a

Medical Device Amendments .............. 156a

DE ONE. Vc én bates eve chu dswasseucns 156a

SE WEE: Nac cacdusncexsckdeewseaenne 167a

SE. Sawai ek ok be kw oh 00 ddb0asecbaskeans 184a

la

APPENDIX A

UNITED STATES COURT OF APPEALS
FOR THE DISTRICT OF COLUMBIA CIRCUIT

Sepremser Term, 1984

No. 84-1025
Contact Lens MANUFACTURERS ASSOCIATION,
Petitioner
v.

Foop & Druc ADMINISTRATION OF THE
DEPARTMENT OF HeaLtH aND Human SERvICEs,
Respondent

Petition for Review of an Order of the
Food & Drug Administration

Before: Rostnson, Chief Judge, WaLp and Grnssure,
Circuit Judges.

[Filed July 9, 1985. George A. Fisher, Clerk]
JUDGMENT

This cause came on to be heard on the petition for review

of an order of the Food & Drug Administration, and was
argued by counsel. On consideration thereof, it is

ORDERED and ADJUDGED, by this Court, that the
petition for review herein is dismissed and the challenged
decision is hereby affirmed, in accordance with the Opinion
for the Court filed herein this date.

Per Curiam
For The Court
/s/ Georce A. FisHER
George A. Fisher
Clerk
Date: July 9, 1985

Opinion for the Court filed by Circuit Judge Ginsburg.

APPENDIX B

United States Court of Appeals

FOR THE DISTRICT OF COLUMBIA CIRCUIT

No. 84-1025
CONTACT LENS MANUFACTURERS ASSOCIATION, PETITIONER
Vv.

Foop & DruG ADMINISTRATION OF THE DEPARTMENT OF
HEALTH AND HUMAN SERVICES, RESPONDENT

Petition for Review of an Order of the
Food & Drug Administration

Argued February 26, 1985
Decided July 9, 1985

' Daniel J. Manelli, with whom Edward A. Scallet was
on the brief, for petitioner.

Beverly Sherman Nash, Attorney, Department of Jus-
tice, Richard K. Willard, Acting Assistant Attorney Gen-
eral, J. Patrick Glynn, Margaret A. Cotter, Mark H.
Gallant, Attorneys, Department of Justice and Michael
M. Landa, Attorney, Food and Drug Administration.

Before: ROBINSON, Chief Judge, WALD and GINSBURG,
Circuit Judges.

3a

Opinion for the Court filed by Circuit Judge GINSBURG.

GINSBURG, Circuit Judge: In 1938, Congress armed
the Food and Drug Administration (FDA) with author-
ity to prevent the marketing of hazardous drugs. By the
mid-1970’s, however, it had become apparent that the
legislature’s delineation of the FDA’s domain was too
narrow to enable the agency to protect the public from
some of the most dangerous health care products. Mind-
ful of recent misfortunes involving faulty pacemakers
and the Dalkon Shield, Congress enacted the Medical
Device Amendments of 1976 (Amendments or statute),
Pub. L. No. 94-295, 90 Stat. 539 (codified at 21 U.S.C.
$§ 360c-360k (1982)), thereby extending the FDA’s pre-
market surveillance field beyond drugs to medical devices.
This case, one of first impression, involves the FDA’s
administration of the Amendments.

Congress’ new prescription for the FDA divided the
world of medical devices into three classes, according to
the degree of regulation thought necessary to provide
reasonable assurance of each device’s “safety and effec-
tiveness.” Class I encompassed devices whose safety and
effectiveness could be reasonably assured by “general con-
trols” set out in various sections of the Food, Drug, and
Cosmetic Act, 21 U.S.C. §§ 301-392 (1982). Class II
covered devices that posed somewhat greater risks; de-
vices placed in this category would be subject to “per-
formance standards” in addition to the residual general
controls. Class III was to obtain devices (1) whose
safety and effectiveness could not be reasonably assured
by any combination of general controls and performance
standards, and (2) whose purported purpose was to aid
in supporting or sustaining human life or preventing its
impairment, or whose availability presented “a potential
unreasonable risk of illness or injury.” No device con-
signed to class III could be sold to the general public
until, through a costly and time-consuming process, it
had gained the FDA’s “premarket approval.” See § 360c
(a) (1) td.

4a

Congress itself was not positioned to determine the
appropriate classification of every medical device then in
existence or yet to be invented; nor could it describe the
statutory categories with sufficient precision to ensure
that each device would simply fall into the proper class
of its own accord. The legislators therefore charged the
FDA with the task of implementing the Amendments,
and thus of essaying judgments appropriate to ensure
safe and effective medical devices without stifling innova-
tive technology. See H.R. Rep. No. 853, 94th Cong., 2d
Sess. 12-13 (1976) [hereinafter cited as House Report).

Congress drew several initial bright lines, however,
that significantly affected the classification process.
“(Devices of a type introduced or delivered for intro-
duction into interstate commerce for commercial distri-
bution” before the date of the Amendments’ enactment
were to remain entirely outside the classification scheme
until the FDA decided where to place them. See 21
U.S.C. § 360¢(c) (3); General Provisions and Classifica-
tion of 119 Devices, 47 Fed. Reg. 3694, 3694 (1982)
{hereinafter cited as Mass Classification Proposal]. De-
vices introduced after the date of enactment, by contrast,
would rank in class III unless shown to belong to a non-
class-III family of devices and to be “substantially equiv-
alent” to a particular, already-marketed device within
that family. See 21 U.S.C. § 360c(f) (1) (A); 21 C.F.R.
$ 860.1384 (1984). Moreover, under provisions labeled
“transitional,” class III ranking automatically attached
to “[a]ny device intended for human use . . . which the
[FDA] in a notice published in the Federal Register be-
fore the enactment date has declared to be a new drug.”
21 U.S.C. § 8360j(/)(1)(E). The FDA could later re-
classify any device that, for whatever reason, had been
“overclassified,” but this remedy required a proffer of
“new information,” id. § 360c(e)—or, as the FDA for-
mulated the standard, “valid scientific evidence” of
safety and effectiveness. 21 C.F.R. §§ 860.7, .123(a) (6).

5a

The instant petition concerns the first attempt ever
to reclassify a medical device committed to class III by
the Amendments’ “transitional provisions.” Contact Lens
Manufacturers Association (CLMA) challenges the FDA’s
withdrawal of the agency’s own proposal to transfer cer-
tain rigid gas permeable (RGP) contact lenses from
class III to class I. 48 Fed. Reg. 56,778 (1983). Claim-
ing that RGP lenses (and hence, RGP lens manufactur-
ers) have suffered disparate treatment in relation to
other medical devices (indeed, other contact lenses),
CLMA urges that “something has gone very wrong
here.” Brief of Petitioner at 2. We conclude, however,
that CLMA’s travails are attributable to the ivtricacies
of the legislation Congress ordered, and to the broad
administrative discretion Congress conferred upon the
FDA. Because our review satisfies us that the FDA has
permissibly exercised its considerable discretion in this
case, we affirm the agency’s action.

I.

Contact lenses consisting almost entirely of polymethyl-
methacrylate (PMMA)—‘“hard” lenses—have been mar-
keted in the United States since the early 1950’s. See
Regulatory Policy and Proposed Rulemaking for Market-
ing Contact Lenses, 40 Fed. Reg. 44,844, 44,845 (1975)
{hereinafter cited as New Drug Notice]. Because the
public’s pre-Amendments experience with PMMA lenses
was broad ard substantially injury-free, see id., these
lenses will remain outside the Amendments’ classifica-
tion scheme until the FDA formally decides where to
place them. See supra p. 3. That decision has not yet
been made; three years ago, however, the FDA proposed
to regulate PMMA lenses as class II devices. See Mass
Classification Proposal, 47 Fed. Reg. at 3736.

Hydroxyethylmethacrylate (HEMA) lenses—‘“soft”
lenses—are a more recent development. The FDA first
approved a HEMA lens in 1971. See 47 Fed. Reg. 53,411,

6a

43,415 (1982). In September 1975, citing their relative
novelty, the FDA announced that HEMA lenses—indeed
all lenses “other than those consisting [almost wholly] of
PMMA”—had been and would continue to be regarded
as “new drugs”:
This decision to regulate such contact lenses under
the new drug provisions of the Federal Food, Drug,
and Cosmetic Act was based on a recognition that
new plastic materials that had not been shown to be
safe and effective were being introduced for use in
the manufacture of contact lenses. The introduction
of these new materials led to new lens design and
use, new manufacturing methods, and new methods
for lens care. The Food and Drug Administration
is concerned that the use of these contact lenses may
result in serious eye damage if the new material of
which they are composed is unsafe for use in the
eye, if the user cannot feasibly care for the lenses,
or if the highly complex procedures for the manu-
facture of these lenses are not carefully controlled
to assure a product of uniform quality.

New Drug Notice, 40 Fed. Reg. at 44,845. This an-
nouncement rendered HEMA lenses class III devices un-
der the Amendments’ “transitional provisions.” See su-
pra p. 3; cf. infra note 3 (rejection of reclassification
proposal).

The product at issue in this case is said to combine
attractive features of both lens types described above.
“RGP lenses” (like “PMMA lenses” or “HEMA lenses”)
is a generic term that indicates no single mix of polymers
or manufacturing process; but all lenses properly called
RGP share certain salient characteristics. The ideal RGP
lens permits both the superior visual acuity attainable
with a hard lens and the “direct transmission of oxygen
to corneal tissue” that the hard lens regrettably prevents.
See 47 Fed. Reg. 53,402, 53,406 (1982) [hereinafter
cited as Reclassification Proposal]. Nearly a million peo-

7a

ple in the United States wore RGP lenses in 1982. /d.'
As of 1975, however, RGP lenses, like soft lenses, were
comparatively new and untested; since enactment of the
Amendments the FDA has regarded RGP lenses as
“transitional” class III devices by reason of the same
September 1975 Federal Register announcement that re-
sulted in placement of HEMA lenses in the class III

category. See supra p. 5; infra pp. 11-12.

Consequently, before a manufacturer can market a
particular RGP lens to the public, the manufacturer
must demonstrate the safety and effectiveness of that
lens convincingly enough to gain the FDA's premarket
approval. “[(I]}n effect,” the manufacturer must obtain
“a license to market the device.” Brief for Respondent
at 5 n.6. (If RGP lenses were class I devices, the manu-
facturer would be required to make the showing CLMA
regards as less burdensome that the lens was “sub-
stantially equivalent” to another RGP lens already on
the market. See 21 U.S.C. § 360c(f)(1)(A) (1982); supra
p. 3. But see infra pp. 17-19.) The expense of obtaining
a class III device ticense—“estimated at $750,000-
$1,000,000 (over and above development costs),” Brief
of Petitioner at 11, the bulk of which goes to clinical
investigation—constitutes a significant barrier to entry.
Not surprisingly, the first and largest of several manu-
facturers to surmount the premarket-approval hurdle,
Syntex Ophthalmics, commands a dominant share of the
market for RGP lenses. CLMA barely disguises its sug-
gestion that Syntex is implicated in the FDA's decision
to hold RGP lenses within the class III regime.

That decision did not follow a steady path. In March
1981 CLMA petitioned the FDA to reclassify RGP lenses
from class III to class II. Pursuant to 21 U.S.C. § 360c¢(b)

1 Counsel for CLMA, demonstrating warm zeal for his
client, informed the court in opening lines of oral argument
that he and his co-counsel were themselves satisfied wearers
of RGP lenses.

8a

(1982), the FDA referred the petition to an expert
advisory committee, the Ophthalmic Section of the Oph-
thalmic; Ear, Nose, and Throat; and Dental Devices
Panel, which recommended the following month that the
petition be granted on the condition that CLMA submit
additional materials. In November 1981 the FDA an-
nounced that although CLMA’s upgraded submissions
continued to be inadequate, “CLMA’s objectives are
meritorious,” and therefore the FDA intended to adopt
the reclassification proposal as the agency’s own. See 46
Fed. Reg. 57,648 (1981). The FDA promised to publish
a formal proposal in a future issue of the Federal Reg-
ister; meanwhile, the agency solicited comment on var-
ious economic issues that appeared unrelated to the
lenses’ safety and effectiveness. See id. at 57,648-49.

In November 1982, a year after the FDA’s initial indi-
cation of interest, the reclassification proposal emerged.”
“Based on a careful review of new, publicly available,
valid scientific evidence,” the proposal stated, “FDA has
tentatively concluded that . . . certain [RGP lenses]
should be reclassified into class I.” Reclassification Pro-
posal, 47 Fed. Reg. at 53,404. The proposal was limited
to spherical lenses consisting of cellulose acetate butyrate
(CAB) or polyacrylate-silicone. Jd. But departing from
CLMA’s original request for class II designation, the
proposal recommended reclassification down to class I.
Although the FDA then “believe[d] that sufficient in-
formation exist[ed] to establish a [class II performance]
standard,” the agency also felt that safety and effective-
ness could be adequately assured without such a stand-
ard. Id. at 53,405-06. The proposal extensively and

2In the interim, FDA represent: ives had been questioned
by members of a House subcommittee about the “rather un-
usual” delay. FDA Oversight: Medical Devices: Hearing
Before the Subcomm. on Oversight and Investigations of the

House Comm. on Energy and Commerce, 97th Cong., 2d Sess. -

3 (1982) (remarks of Rep. Whittaker) ; see id. at 29-34, 95-
96, 104-06.

9a

favorably discussed the clinical data cited by reclassifica-
tion proponents. Nevertheless, the FDA invited comment
on a range of issues including the following:

1. Do the data presented in this proposal consti-
tute sufficient “valid scientific evidence’ of safety
and effectiveness to support reclassification of each
(currently] marketed lens [and any lens that might
be created] consisting of CAB or polyacrylate-
silicone?

4. Does specifying the materials of which the
lenses proposed for reclassification are principally
composed adequately identify the lenses for the pur-
pose of reclassification?

Id. at 53,410.

The uncertainty intimated by these questions soon be-
came palpable. On December 10, 1982, the FDA extended
the comment period thirty days, till January 26, 1983.
47 Fed. Reg. 55,497 (1982). On April 15, 1983, the
comment period was reopened. 48 Fed. Reg. 16,293
(1983). A public hearing was held on May 26, 1983,
followed by yet another fifteen-day comment period. See
48 Fed. Reg. 18,836 (1983). Finally, on December 23,
1988, CLMA’s once high expectations for the RGP pro-
posal ended: the FDA repudiated its “tentative con-
clusions” and withdrew its reclassification proposal al-
together. 48 Fed. Reg. 56,778 (1983).°

’CLMA’s petition to reclassify HEMA lenses underwent a
parallel odyssey and met an identical fate. Finding CLMA’s
January 1981 proposal deficient, the FDA itself took up the
reclassification cause. 46 Fed. Reg. 57,648 (1981). A year
later, the FDA formulated an official proposal to transfer
HEMA lenses from class III to class I, and asked for com-
ments. 47 Fed. Reg. 53,411 (1982). After enlarging the
comment period, reopening it, holding a public hearing, and
receiving more comments, the FDA killed the proposal on
April 24, 1984. 49 Fed. Reg. 17,523 (1984).

10a

The FDA attributed its changed view to “comments
and oral and written testimony that required it to re-
evaluate the evidence upon which it relied in the pro-
posal, and to evaluate additional information.” Jd. at
56,781. First, the agency explained, various commenters
had demonstrated that the clinical studies cited as proof
of the safety and effectiveness of CAB and polyacrylate-
silicone lenses * then on the market did not, after all, add
up to “valid scientific evidence.” Jd. at 56,780. Second,
even if the studies did constitute such evidence, they were
“insufficient to justify reclassification” because they
“fail[ed] to establish the safety and effectiveness of
[RGP] lenses as a generic type of device.” Jd. Given
the countless conceivable combinations of “polymer formu-
lation and manufacturing processes,” and the correspond-
ing variations in lenses’ “nontoxicity, biocompatibility,
[and] light transmission,” the FDA could not conclude
that mere membership in the family of “RGP lenses”
clinched any particular lens’ safety and effectiveness. Jd.

The FDA thus determined that no reclassification of
RGP lenses could provide reasonable assurance of safety
and effectiveness: class I status was not feasible because
the FDA could not determine whether a new lens was
“substantially equivalent” to an already-marketed lens
without securing a wealth of detailed information about
both lenses’ composition and manufacture; and class II
status was not in order because, even if such informa-
tion could be gathered for the purpose of establishing a
“performance standard’ and measuring new lenses
against it, conformity with the standard would not guar-
antee that a lens would function safely and effectively in
the human eye. Jd. at 56,780-81. “In short, FDA learned
that at this stage in [RGP lens] development, there is no

4The petition for review concerns only the FDA’s treat-
ment of polyacrylate-silicone lenses. Brief of Petitioner at 8
n.4. Accordingly, the term “RGP lenses,” as henceforth used
in this opinion, denotes lenses made of polyacrylate-silicone.

lla

substitute for clinical trials [i.e., class III status] to
provide reasonable assurance of the safety and effective-
ness of these lenses.” Jd. at 56,781.

CLMA complains, in petitioning for review, that the
FDA has disregarded a medical consensus favoring re-
classification and has rendered insensible the requirement
of “valid scientific evidence.” We recognize substantial
merit in CLMA’s argument that RGP lenses should not
be locked within so tight a regulatory regime. Nonethe-
less, we cannot disturb the FDA’s decision. The agency
acted within an area of its expertise, it ruled in a man-
ner at least arguably consistent with the statutory scheme,
and it considered the matter in a detailed, adequately
reasoned fashion. We therefore defer to the agency and
affirm its judgment. See Chevron, U.S.A., Inc. v. Natural
Resources Defense Council, 104 S. Ct. 2778, 2782-83
(1984) ; Rettig v. Pension Benefit Guaranty Corp., 744
F.2d 138, 151 (D.C. Cir. 1984) (quoting Chevron).

II.

We address at the outset CLMA arguments that the
entire reclassification project was misconceived because
RGP lenses were never class III devices to begin with.
FDA’s responses * indicate, correctly as we see the regu-

° The FDA initially asserts that we lack “jurisdiction” to
consider these arguments “because CLMA did not raise them
in the rulemaking proceeding.” Brief for Respondent at 51.
If the arguments were placed before the agency, however, we
may review them even if CLMA was not the presenter. See
Toy Mfrs. of Am. v. Consumer Prod. Safety Comm’n, 630
F.2d 70, 73 n.5 (2d Cir. 1980); see also Lorion v. United
States NRC, 712 F.2d 1472, 1474 (D.C. Cir. 1983) (court
reviews “only those contentions subjected to agency scrutiny
during the administrative process”), rev’d on other grounds
sub nom. Florida Power & Light Co. v. Iorion, 105 S. Ct.
1598 (1985). Inspection of the challenged withdrawal notice
reveals that the arguments in question, or substantially
similar ones, were in fact rehearsed before the agency.

12a

latory scheme, the limitations of the categories Congress
established.

First, CLMA maintains that RGP lenses are not prop-
erly drawn into the web of the Amendments’ “transi-
tional provisions.” The provision in question assigns to
class III “[{a]ny device intended for human use...
which the [FDA] in a notice published in the Federal
Register before the enactment date has declared to be a
new drug.” 21 U.S.C. § 360j(/) (1) (E) (1982). The
FDA identifies its September 1975 announcement of
“Regulatory Policy and Proposed Rulemaking for Market-
ing Contact Lenses,” see supra p. 5, as the relevant
notice. CLMA characterizes that notice as a preliminary
announcement, merely a proposal for a declaration of
new drug status, not the declaration itself. Brief of
Petitioner at 52.

The asserted distinction between declaration and pro-
posed declaration, in the context of the Amendments,
lacks persuasive force. The statute requires only notice—
not, for example, notice tested in the crucible of public
comment. Further, to the extent that CLMA’s argument
rests not on statutory interpretation but on construction
of the September 1975 declaration as tentative, we can-
not agree. The announcement conveys the distinct im-
pression that regulation of non-PMMA lenses as “new
drugs” was a fait accompli, at that stage missing only
a formal seal:

The policy of the [FDA] of regarding all contact
lenses other than those consisting [almost] entirely
of PMMA as new drugs has been publicized and is
generally known to contact lens manufacturers... .

Although the Agency’s enforcement policy regard-
ing contact lenses has previously been publicized,
this policy is not set forth in Title 21 of the Code
of Federal Regulations. Accordingly, the Commis-
sioner of Food and Drugs has concluded that, for-

l3a

mally to advise the public, this regulatory policy
should be promulgated as a regulation and codified
in Title 21, C.F.R.

New Drug Notice, 40 Fed. Reg. at 44,845.°

Second, CLMA contends that RGP lenses are “custom
devices” as that term is defined in the Amendments, and
are on that account exempt from the classification scheme.
A “custom device” is

any device which, in order to comply with the order
of an individual physician or dentist . . . necessarily
deviates from an otherwise applicable performance
standard or [premarket approval] requirement .. .
if (1) the device is not generally available in finished

*CLMA also suggests that the September 1975 announce-
ment was inadequate in that it “did not mention polyacrylate-
silicone lenses. The only polymers specifically mentioned were
CAB ..., polycarbonate, silicone, and HEMA, types of con-
tact lenses which are readily distinguishable from poly-
acrylate silicone.” Brief of Petitioner at 53. But the list to
which CLMA refers did not purport to be exclusive. It merely
cited examples of contact lens materials about whose safety
and effectiveness the FDA was particularly concerned—ma-
terials “other than PMMA.” New Drug Notice, 40 Fed. Reg.
at 44,845. Polyacrylate-silicone, CLL.MA does not deny, is a
further example of such material.

Our view that RGP lenses were covered by the September
1975 announcement, and are therefore properly ranked as
class III devices under the Amendments’ transitional provi-
sions, suffices to answer CLMA’s further contention that
these lenses merit less stringent regulation because of their
“substantial equivalen[ce]” to PMMA lenses. See Brief of
Petitioner at 61-63. The 1975 announcement, and subsequent
FDA glosses on it, foreclose any argument that RGP lenses
and lenses made almost entirely of PMMA instance the same
“type of device”; thus, there is no occasion for a substantial-
equivalence determination. See 21 U.S.C. § 360c(f) (1) (A)
(1982); cf. 21 C.F.-R. § 860.84 (1984) (distinguishing, for
classification purposes, between (1) devices substantially
equivalent to pre-Amendments devices, and (2) devices regu-
lated as “new drugs”’).

l4a

form for purchase or for dispensing upon prescrip-
tion and is not offered through labeling or advertis-
ing by the manufacturer, importer, or distributor
thereof for commercial distribution, and (2) such
device—

(A) (i) is intended for use by an individual
patient named in such order of such physician
or dentist . . . and is to be made in a specific
form for such patient, [and]

(B) is not generally available to or generally
used by other physicians or dentists ....

21 U.S.C. § 360j(b) (1982). The definition is an eyeful,
but essentially it appears to reflect a commonsense con-
gressional judgment that the design and composition of
certain medical devices are so individualized that sub-
jecting them to the usual regulatory controls would be
impractical (and a complementary judgment that such
particularly constructed devices are so closely monitored
by the prescribing physician that stringent regulation
might well be excessive). The House Report on the
Amendments lists as examples of custom devices “ortho-
pedic and other prosthetic devices, dental devices, and
specially-designed orthopedic footwear”; the same report
cautions that invocation of the exemption must be
“limited.” HOUSE REPORT, supra p. 3, at 44.

We are satisfied that the FDA acted reasonably in re-
fusing to accord custom-device status to RGP lenses. It
suffices to observe that the FDA could rationally regard
such lenses as “generally available to or generally used
by other physicians.” CLMA’s argument to the contrary
focuses obsessively on the individual lens ground to a
particular doctor’s specifications; CLMA disregards the
consideration, urged by the FDA, that the statutory
language is most sensibly read as referring to a more or
less inclusive class of devices rather than to any given
exemplar of the class. And even if the relevant question

lda

were whether a specifically prescribed lens was “gen-
erally available to or generally used by other physicians,”
there would be force to the FDA’s contention that any
specimen lens “is merely a variation within an approved
range of powers and anterior and posterior surface con-
tours.” Brief for Respondent at 62. In other words,
prescriptions for all but the most pathological eyes are
likely to be replicated again and again and thus to be
“generally used.” CLMA insists that this construction
of “generally used” could as easily lead to a ruling that
orthopedic shoes are not “custom devices.” But insofar
as the FDA’s conclusion from the logic and language of
the statute appears contrary to the result intimated by
some of the examples of “custom devices” offered in the
legislative history, the FDA has: properly cast its lot
with the former. See, e.g., Eagle-Picher Industries v.
United States EPA, 759 F.2d 922, 929 (D.C. Cir. 1985).

In short, it appears to us from the arguments made
that the premise on which the FDA's initial reclassifica-
tion proposal rested—that RGP lenses are currently class
III devices—is altogether reasonable. The critical ques-
tion that remains is whether the FDA could rationally
refuse to bring its reclassification proposal to fruition.

Il.

The FDA has consistently maintained that proponents
of reclassification assume the burden of demonstrating—
through “publicly available, valid scientific evidence’”—
that the device’s present classification is inappropriate
and that the proposed classification will provide reason-
able assurance of the device’s safety and effectiveness.
See, e.g., 48 Fed. Reg. at 56,779. We cannot fault the
FDA’s assignment of the burden of proof to those seek-
ing to change the status quo. See, e.g., HOUSE REPORT,
supra p. 3, at 40. Thus, CLMA’s claim that maintenance
of class III status for RGP lenses lacks record support,

16a

even if true, is off target. More to the point, CLMA
asserts that the FDA in these proceedings has adopted
an unreasonably strict view of what constitutes “valid
scientific evidence.” Though CLMA presses this argu-
ment with vigor, we are mindful that in such matters
generalist courts see through a glass darkly and should
be especially reluctant to upset an expert agency’s judg-
ment that a party has failed to adduce sufficient scien-
tific proof of safety and effectiveness.

The FDA’s rationale for withdrawing its reclassifica-
tion proposal opens with the rather belated assertion that
nothing in the record establishes the safety and effective-
ness of RGP lenses now on the market. Facets of this
position are unsettling. In justification of its current
stance, the FDA disparaged, see 48 Fed. Reg. at 56,784-
85, the same studies it had once acclaimed, see Reclassifi-
cation Proposal, 47 Fed. Reg. at 53,406-09, and retracted,
see 48 Fed. Reg. at 56,783, its earlier assertion that
“(t]he safety of the device also is shown by the absence
of reports in the literature of serious, irreversible ad-
verse effects on health presented by the device,” see Re-
classification Proposal, 47 Fed. Reg. at 53,405. But the
reclassification proposal specifically asked for comment on
whether “the data . . . constitute sufficient ‘valid scien-
tific evidence.” Jd. at 53,410. We would be denying
the value of notice-and-comment rulemaking were we
to condemn the FDA for altering its outlook on the basis
of submissions it received.

Citing its regulation declaring that “|[i]solated case
reports, random experience, reports lacking sufficient de-
tails to permit scientific evaluation, and unsubstantiated
opinions are not regarded as valid scientific evidence to
show safety or effectiveness,” 21 C.F.R. § 860.7(c) (2)
(1984), the FDA discounted the praises sung by dozens
of “contact lens professionals” who favored reclassifica-
tion and who reported that none of their patients had ever
experienced serious problems with RGP lenses. 48 Fed.

17a

Reg. at 56,786-87. We find the FDA’s categorical be-
littiement of these eyewitness comments somewhat numb-
ing, but we cannot gainsay the FDA’s judgment that
although such testimonials may suffice to disprove safety
and effectiveness, they fail to establish with scientific
rigor the absence of danger. See 21 C.F.R. § 860.7(c) (2).

The FDA’s ultimate resistance to conceding the safety
and effectiveness of lenses now on the market is perhaps
most remarkable because these are the very lenses al-
ready granted premarket approval on the application of
particular manufacturers. The agency's demand for com-
pelling proof on matters presumably demonstrated to it
convincingly by the licensed manufacturers, however, is
a conundrum the statute itself sets up. Under the
Amendments, trade secret information that a manu-
facturer submits to secure premarket approval may not
be cited by the FDA or any third party in aid of re-
classification proposals. 21 U.S.C. § 360j(c), (h) (3)
(1982). Much as in patent law, Congress has determined
that free riding is too high a price to pay for vigorous
competition among medical device manufacturers;? the
FDA is not at liberty to disregard this determination.

Of decisive importance, however, the FDA’s refusal to
reclassify RGP lenses does not stand or fall with the
FDA’s limited-purpose agnosticism about the safety and
effectiveness of lenses currently on the market. Inde
pendently sufficient and far more persuasive is the FDA’s

oo

* As the legislative history explains:

To use trade secret information submitted in connection
with a class III device as the basis for “downgrading” it
into class II status—and thus allowing it to be replicated
by competitors to conform to a standard—would destroy
the originator’s competitive advantage and could serve
to stifle the initiative for innovation.

HOUSE REPORT, supra p. 3, at 50.

18a

determination that all reclassification proposals to date
“inadequately characterize” the class of RGP lenses.
That is, even if the available evidence demonstrates the
safety and effectiveness of lenses already on the market,
this evidence cannot be taken as proof that any RGP
lens a manufacturer might create will meet the statu-
tory requirements; thus, at least for the present, the pre-
market approval process is unavoidable. “[T]he safety
and effectiveness of a contact lens is a function of the
complex interrelationship of material, design, and manu-
facture that results in a unique set of physical, chemical,
mechanical, and optical characteristics.” 48 Fed. Reg. at
56,792. Alter any one of these variables, the FDA now
maintains, and you have a unique new lens whose safety
and effectiveness are unknown and, without thorough
clinical testing, unknowable. To be sure, the reclassifica-
tion proposal described RGP lenses generically in glow-
ing terms: “Contact lenses composed of . . . polyacrylate-
silicone are characterized as chemically and physically
stable under the conditions of their intended use, opti-
cally clear, nontoxic, and nonallergenic.” Reclassification
Proposal, 47 Fed. Reg. at 53,404. But in retrospective
clarification, the FDA explains this statement as the
depiction of a paradigm rather than an assertion that
every potential combination of RGP materials, design,
and manufacture will prove safe and effective.

The inadequacy of generic characterization of RGP
lenses thus emerges as a mainstay of the FDA’s conten-
tion that nothing short of lens-by-lens clinical testing
and premarket approval will ensure safety and effective
ness. If RGP lenses were class I devices, the FDA would
have no firmer basis on which to divine the safety and
effectiveness of new lenses than a ninety-day inquiry into
whether the lenses were “substantially equivalent” to other
lenses already on the market. See 21 U.S.C. § 360(k),
360c(f)(1)(A) (1982); 21 C.F.R. § 807.87 (1984). In
its reclassification proposal, the FDA asserted that such

19a

an inquiry would suffice—provided, however, that the
prospective manufacturer was

prepared to demonstrate substantial equivalence in
terms including, but not limited to, design; composi-
tion; optical transmission (and homogeneity) and
index of refraction; and other physical properties
including oxygen permeability, chemical and physical
stability, tensile and flexural strength; biocompati-
bility, including cytotoxicity, eye irritation, and non-
support of bacterial growth; impurities; leachables;
heavy metal levels; preservative uptake and release;
. . . lens care/cleaning regimen compatibility! ; and
manufacturing process].

Reclassification Proposal, 47 Fed. Reg. at 53,405.

The detail of this checklist suggests that, from the
start, the FDA felt insecure about reclassifying RGP
lenses. Upon withdrawing its proposal, the FDA an-
nounced its tardy recognition that the contemplated sub-
mission would be “indistinguishable”’ from the data re-
quired in a premarket approval application. 48 Fed.
Reg. at 56,790. In other words, on close inspection, the
FDA determined that class I assignment simply was not
feasible. Given the detailed data submission necessary
to find “substantial equivalence,” prospective RGP lens
manufacturers would be put to a burden approaching
that entailed by the premarket approval process. At the
same time, appraising such evidence “on a comparison
basis” rather than for the purpose of “determin[ing] the
safety and effectiveness of a device in the first instance,”
id., would be both difficult and constraining. Not only
would the problem of trade secret information, see supra
p. 16, impede comparative evaluation; in addition, the
exacting character of the comparisons involved might dis-
courage innovation by requiring the manufacturer of a
new RGP lens to demonstrate “substantial equivalence”
almost to the point of patent infringement. See, e.g.,

20a

Joint Appendix (J.A.) at 334 (comments of Dow Corning
Ophthalmics) .*

The FDA’s doubts about generic characterization of
RGP lenses led it to conclude as well that class II “per-
formance standards,” such as those formulated by the
American National Standards Institute, would fail to
provide reasonable assurance of safety and effectiveness.
See 48 Fed. Reg. at 56,791. Although compliance with
such standards may be easy to measure and may attest
to a lens’ physical, chemical, and optical integrity, the
FDA observes that there is no scientifically proven rela-
tionship between fulfillment of the laboratory criteria
and performance in the human eye.

On its face, the proposition that “minor changes in
lens material formulation or manufacturing process can
significantly [and unpredictably] affect the safety and
effectiveness of lenses manufactured from the material,”
id. at 56,780, appears at least plausible. Indeed, a di-
luted form of this proposition—the chance that “there
may conceivably be polymeric combinations within the
category of polyacrylate-silicone which are not suitable
for making RGP lenses”—-strikes CLMA as “self-evident.”
Brief of Petitioner at 47. CLMA’s complaint is that the
imposition of expensive clinical testing requirements on
each new type of RGP lens—requirements to which
fewer than five percent of all medical devices are sub-
ject, see id. at 6 & n.3—is wholly out of proportion to
the lenses’ capacity for mischief.

*In discussing the “substantially equivalent” test, the
Amendments’ legislative history confirms that the FDA is
well within its discretion in declining to attempt comparison
of devices that are disparate in such important respects as
composition or design: “differences between ‘new’ and mar-
keted devices in materials [or] design . . . would have a bear-
ing on the adequacy of information as to a new device's
safety and effectiveness, and such [new] devices should be
automatically classified into class III.” House REPoRt, supra
p. 3, at 36.

2la

Given the record before the FDA, however, the agency
could responsibly conclude that novel RGP lenses pose
“a potential unreasonable risk of illness or injury.” 21
U.S.C. § 360c(a)(1)(C) (1982) (describing conditions
under which FDA may place pre-Amendments device
in class III); see, e.g., J.A. 339 (comments of David M.
Worthen, M.D.); id. at 354, 357 (comments of Syntex
Ophthalmics, Inc.); id. at 381 (comments of Barnes-
Hind/Hydrocurve, Inc.) ; see also Brief for Respondent
at 53-55 (arguing that, in any event, CLMA failed to
demonstrate the nonexistence of such risk). It is true
that companies like Syntex Ophthalmics, whose RGP
lenses had already won premarket approval, were the
principal doomsayers. But their apparent interest does
not render their comment valueless. See National Soft
Drink Association v. Block, 721 F.2d 1348, 1354 (D.C.
Cir. 1983) (“We do not weigh the evidence; we merely
examine the record to see if there is evidence, which if

accepted by the Secretary, supports the determination of
the agency.”).°

*CLMA further contends that the FDA abused its discre
tion by failing to consider the controlled clinical setting in
which contact lenses are prescribed and fitted. The safety and
effectiveness of a device are to be determined, in part, “with
respect to the conditions of use prescribed, recommended,
or suggested in the labeling of the device.” 21 U.S.C.
§ 360c(a)(2)(B) (1982). CLMA argues that RGP lenses
present no risk of irreversible injury; rather, the patient's
eyes simply get a little red, at which point his optometrist or
ophthalmologist orders a different sort of lens. Brief of Peti-
tioner at 33; see Reply Brief of Petitioner at 12 (in this
manner, competition will weed out unsafe and ineffective
lenses without the need for FDA supervision).

The FDA usefully might have supplied a more explicit
t of the context in which RGP lenses are

marketed, and a fuller explanation of why that context does
not obviate the need for strict regulation. Cf. 48 Fed. Reg.
at 56,787-88 (denying that medical supervision justifies en-
largement of reclassification proposal to encompass nonspheri-
cal lens designs about whose safety and effectiveness there is

22a

We are troubled, nonetheless, by the argument that
the FDA’s treatment of RGP lenses, even if internally
logical and supported by several comments in the record,
is impeached by the agency’s action in other dockets.
Comparative sideglances, CLMA contends, demonstrate
graphically that RGP lenses have received an inordi-
nately hard look. For example, in January 1982, the
FDA proposed to classify 119 previously unclassified oph-
thalmic devices already on the market when Congress
passed the Amendments; in that proposal, the FDA de-
scribed “artificial eyes” generically as devices “usually
made of glass or plastic,” without any suggestion that a
more precise specification of materials or manufacturing
processes might be necessary. Mass Classification Pro-
posal, 47 Fed. Reg. at 3724. It may make sense to say
that devices designed for prolonged contact with so
delicate and vital an organ as the living eye merit more
circumspect regulation than do devices that merely stand
in for that organ once it is lost; to the extent that this
proposition is intuitively obvious, the FDA may be for-
given for not stating it. But how does the FDA account
for its proposal, id. at 3736, to regulate PMMA lenses
as class II devices? Is it not myopic for the FDA to
ignore the variations in materials and manufacture of
devices that appear to present risks of the same order
as those posed by RGP lenses—devices that, in fact,
raise the additional problem of depriving the cornea of
oxygen?

The FDA implies that PMMA lenses’ “extensive his-
tory of safe and effective human use” justifies a more
lenient form of regulation. See 48 Fed. Reg. at 56,787.

a “complete lack” of evidence). But CLMA’s argument ap-
pears rooted in a premise the FDA has quite clearly rejected
—that the risks posed by RGP lenses are too inconsequential
to merit prior regulatory restraints. And surely the infamous
histories of the two devices that principally inspired the
Amendments, see supra p. 2, belie the assertion that the
participation of a doctor renders premarket approval un-
necessary.

nse lala

Ye ee eed ~

23a

This response is not altogether satisfactory. Although an
“extensive history of safe and effective human use” may
constitute, or obviate the need for, “valid scientific evi-
dence” of the safety and effectiveness of PMMA lenses
currently on the market,'® it cannot—by the FDA’s own
hypothesis—inform us about lenses that as yet are but
a glimmer in a polymer chemist’s eye. Perhaps the range
of possibilities is narrower, the predictability of results
greater, for PMMA lenses than for RGP lenses. Cf.
48 Fed. Reg. at 56,787 (suggesting “potential significant
differences in . . . uniformity” between PMMA and
RGP lenses). If not, we would be hard-pressed to recon-
cile differential classification of the two devices. See
also J.A. 388 (comments of Precision-Cosmet Co.) (crit-
icizing “the ‘hard lens attitude’ in the industry which
is essentially [that] one will do just as one pleases, since
‘hard’ lenses have never hurt anyone’”’).

But the issue is not ripe for our consideration. The
FDA acts on classification initiatives at a pace fairly

10Tn its proposal to classify 119 ophthalmic devices, for
instance, the FDA validated its advisory panel’s reliance on
essentially anecdotal evidence:

In many cases, the Panel based its recommendations on
Panel members’ personal knowledge of, and clinical ex-
perience with, the devices under review. The Panel
particularly relied upon clinical experience and judgment
when considering a «imple device that had been used
extensively and was accepted widely before the amend-
ments were enacted. ... FDA has determined that
clinical experience and judgment is valid scientific evi-
dence for classifying certain devices.

Mass Classification Proposal, 47 Fed. Reg. at 3696. The
panel’s recommendation regarding PMMA lenses seems to
have been based on the same sort of evidence. See id. at
3736. By the year 2000, therefore, if the FDA follows a
consistent course, we would expect questions about the safety
and effectiveness of lenses already on the market, see supra
pp. 15-16, to pose no continuing impediment to reclassification
of RGP lenses.

24a

described as glacial. The January 1982 proposal to
place PMMA lenses in class II remains only a proposal.
Since that proposal antedates by almost two years the
CLMA-challenged withdrawal of the proposed reclassi-
fication of RGP lenses, we would not be surprised if the
FDA were having second thoughts. We do not prejudge
the appropriate classification of PMMA lenses; we sug-
gest only that, should the FDA ultimately decide to treat
PMMA and RGP lenses differently, we will not feel that
our respect for the agency’s judgment has been vindi-
cated unless the FDA explains why such a distinction is
coherent. In the meantime PMMA lenses continue to be
entirely free of any classification, but that is the way
the statute Congress designed works.

IV.

We are cognizant of the ironies effected by the statute
and the FDA’s initially insecure administration of it. Con-
sidering the difficulty of the assignment Congress entrusted
to the agency, and the respect we owe to the FDA’s
expert judgment, however, we cannot say that the action
we have been asked to review is unlawful. Many of
CLMA’s claims of inequitable treatment are better
addressed to Congress; others are not yet ripe. We hold
simply and only that at this juncture, the FDA has not
been shown to have proceeded without reason or regard
for the statute in withdrawing its proposal to reclassify
RGP lenses. The petition for review is accordingly dis-
missed and the challenged decision is

Affirmed.

ae

25a
APPENDIX C
UNITED STATES COURT OF APPEALS
FOR THE DISTRICT OF COLUMBIA CIRCUIT
SreprEMBER TERM, 1984

No. 84-1025

Contact Lens Manuracturers ASSOCIATION
Vv.

Foop anp Druc ADMINISTRATION OF THE
DepaRTMENT OF HEALTH AND Human SERVICES

[Filed September 10, 1985. George A. Fisher, Clerk]

ORDER
Upon consideration of petitioner’s petition for rehearing,
it is
ORDERED, by the Court, that the petition is denied.
Per Curiam
For Tue Court

Georce A. FisHer, CLERK

By: /s/ Rospert A. BonNER
Robert A. Bonner
Chief Deputy Clerk

26a
APPENDIX D

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION
21 CFR Parr 886
[Docket No. 82N-0180]

RECLASSIFICATION OF DAILY WEAR SPHERICAL CON-
TACT LENSES CONSISTING OF RIGID GAS PERMEABLE
MATERIALS; WITHDRAWAL OF PROPOSED RULE

AGENCY: Food and Drug Administration.
ACTION: Withdrawal of proposed rule.

SUMMARY: The Food and Drug Administration (FDA) is
withdrawing its proposed rule to reclassify marketed daily
wear spherical contact lenses consisting of certain rigid
gas permeable plastic materials from class III (premarket
approval) into class I (general controls). FDA has deter-
mined, after providing two opportunities for submission of
comments and evidence, after holding a public hearing fol-
lowed by an additional period for submission of comments
and evidence, and after reconsidering the basis for FDA’s
tentative conclusion that class I would provide reasonable
assurance of the safety and effectiveness of the device,
that there is insufficient new, publicly available, valid scien-
tific evidence to show that the device is safe and effective.
to characterize the device adequately for the purpose of
reclassification, or to demonstrate that either class I or
class II (performance standards) would provide reason-
able assurance of the safety and effectiveness of the device.
Class IIIvis necessary to provide such assurance.

EFFECTIVE DATE: (Insert date of publication in the
FEDERAL REGISTER.)

Nha altace etiam

27a

FOR FURTHER INFORMATION CONTACT:

Albert Van de Griek,

National Center for Devices and Radiological Heaith
(HFK-402),

Food and Drug Administration,

8757 Georgia Ave.,

Silver Spring, MD 29010,

301-427-8162.

SUPPLEMENTARY INFORMATION:

For the convenience of the reader, the following is an
index of the sections throughout this document:

I. History of the Proceedings.

II. Overview of the Basis for FDA’s Decision.

A. Background.

B. Insufficient Evidence of Safety and Effective-
ness.

C. Inadequate Characterization of Materials.

D. Inadequacy of Class I or Class II to Provide
Reasonable Assurance of Safety and Effective-
ness.

E. Need for Clinical Trials.

F. Conclusion.

Il. Analysis of Comments.

Classification.

Identification.

Adequacy of Safety and Effectiveness Data.
Adequacy of Characterization.

Adequacy of General Controls.

Adequacy of Class IT.

Need for Clinical Trials.

. Economic Impact of Reclassification.

Beas IAD>

28a

I. Contact Lens Accessories.
J. Tinted Contact Lenses.
K. Miscellaneous Matters.

IV. References.

I. HISTORY OF THE PROCEEDINGS

In the FEDERAL REGISTER of November 26, 1982
(47 FR 53402), FDA published a proposed rule to re-
classify marketed daily wear spherical contact lenses con-
sisting of certain rigid gas permeable plastic materials
from class III into class I. (For convenience, the lenses
proposed for reclassification are referred to throughout
this document as rigid gas permeable lenses and all other
references to lenses refer to contact lenses.) Interested
persons were given until December 27, 1982, to comment
on the proposal. In the FEDERAL REGISTER of Decem-
ber 10, 1982 (47 FR 55497), FDA extended the comment
period to January 26, 1983. Following a review of the
eomments received during this period, FDA determined
that resolution of complex scientific issues raised by the
comments would be facilitated by reopening the comment
period to receive additional information on certain specific
issues. Therefore, in the FEDERAL REGISTER of April
15, 1983 (48 FR 16293), FDA reopened the comment period
for 30 days. Several requests for a public hearing before
the Commissioner of Food and Drugs were received. In
the FEDERAL REGISTER of April 26, 1983 (48 FR
18836). FDA announced that a public hearing would be
held to afford interested persons an opportunity to present
information and views on the issues involved in the re-
classification proceeding. The hearing, which was held on
Mav 26, 1983. was followed by an additional 15-day com-
ment period to allow ;»cerested persons to submit written
comments on matters raised at the hearing. The comment
- period following the hearing closed on June 10, 1983.

29a

i. OVERVIEW OF THE BASIS FOR FDA’S DECISION
A. Background

Section 513(e) of the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 360c(e)) authorizes FDA to re-
classify a device based on ‘‘new information’’ respecting
the device. (See the preamble to the proposed rule (47 FR
53404) for a comprehensive discussion of the meaning of
the term ‘‘new information.’’) The ‘‘new information’’ on
which any reclassification of a device is based is required
to consist of ‘‘valid scientific evidence,’’ as defined in
§ 860.7 of the regulations governing medical device classi-
fication procedures (21 CFR 860.7). FDA relies only upon
such evidence to determine whether there is reasonable
assurance that a device is safe and effective (§ 860.7(c)(1)).
As the agenev explained in the preamble to the final rule
establishing Part 860 (21 CFR Part 860), the purpose of
the Medical Device Amendments of 1976 (Pub. L. 94-295)
(the amendments) is to assure the safety and effectiveness
of medical devices intended for human use and such assur-
ance necessarily demands a high standard of proof (43
FR 32988 ; July 28. 1978).

For the purpose of reclassification, the valid scientific
evidence upon which the agency relies is required to be
publicly available, i.e., may not be based on trade secret
or confidential commercia! information in any premarket
approval application (PMA) for a medical device or on
trade secret or confidential commercial information from
any investigation concerning the safety and effectiveness
of a device (section 520(c) of the act (21 U.S.C. 360j(c)).
Such valid scientific evidence also may not be based upon
the detailed summary of information respecting the safety
and effectiveness of any device for which there is an ap-
proved PMA (section 520(h)(3) of the act) and which
FDA is required to make available to the public upon
issuance of an order approving a PMA (section 520(h) (1)
of the act).

30a

In the preamble to the proposed rule (47 FR 53404),
FDA stated:

To reclassify a device under section 513(e) of the
act, the statute and the regulations require that the
new, publicly available, valid scientific evidence of
safety and effectiveness show (1) why the device
should not remain in its present classification and
(2) that the proposed reclassification will provide rea-
sonable assurance of the safety and effectiveness of
the device. In the case of a device classified in class
III and proposed for reclassification into class I, the
statute and the regulations require such evidence of
safety and effectiveness to show (1) why the device
should not remain in class III and (2) that general
controls will provide reasonable assurance of the safe-
ty and effectiveness of the device.

The general controls are those authorized by or under
sections 501 (adulteration), 502 (misbranding), 510 (regis-
tration, listing, and premarket notification), 516 (banned
devices), 518 (notification and other remedies), 519 (rec-
ords and reports), and 520 (general provisions including
current good manufacturing practice requirements) of the
act (21 U.S.C. 351, 352, 360, 360f, 360h, 350i, and 360j).

In the preamble to the proposed rule, FDA summarized
the data on which the proposed reclassification was based
(47 FR 53406-53409) and tentatively concluded that rigid
gas permeable lenses should be reclassified into class I,
rather than into class IT upon the effective date of a per-
formance standard established under section 514 of the act
(21 U.S.C. 360d) (47 FR 53404). In FDA’s judgment at
that time, the information discussed in the preamble showed
that the device was safe and effective for its intended use.
FDA also believed that the general controls provisions of
the act would be sufficient to provide reasonable assurance
of the safetv and effectiveness of the device. The decision

3la

to propose reclassification into class I, rather than class IT
once a performance standard was established, was based
on FDA’s belief that although sufficient information existed
to establish a standard to provide reasonable assurance of
the safety and effectiveness of rigid gas permeable lenses,
there was no need to establish a performance standard to
provide such assurance.

Issuance of a proposed rule to reclassify a device from
class III into class I under section 513(e) of the act does
not preclude promulgation of a final rule to reclassify the
device into class II, if the evidence warrants such action,
particularly where, as in this proceeding, the preamble to
the proposed rule invited comments on the appropriateness
of reclassification into class II, before or after the estab-
lishment of a performance standard under section 514 of
the act for the device. A class II device is one for which
general controls by themselves are insufficient to provide
reasonable assurance of the safety and effectiveness of the
device. for which there is sufficient information to establish
a performance standard to provide such assurance, and
for which ‘‘it is therefore necessary to establish * * * 9
performance standard under section 514 to provide reason-
able assurance of its safety and effectiveness’’ (section
513(a)(1)(B) of the act; 21 CFR 860.3(c)(2)).

Tn the preamble to the proposed rule (47 FR 53410).
FDA invited comments on several specific issnes inelvding
the following questions:

1. Do the data presented in this proposal constitute
sufficient ‘‘valid scientific evidence’? of safetv and
effectiveness to support reclassification of each mar-
keted lens consisting of CAB or polyacrylate-silicone?

a. If not, what additional publicly available data are
there to support reclassification?

b. If so, are general controls sufficient to provide
reasonable assurance of the safety and effectiveness
of the device?

32a

c. If general controls are not sufficient to provide
reasonable assurance of the safety and effectiveness
of the device, is there sufficient information to estab-
lish a performance standard to provide such assur-
ance?

d. If general controls are not sufficient, and there
is sufficient information to establish a performance
standard to provide reasonable assurance of [the]
safety and effectiveness of the device, is a perform-
ance standard necessary to assure any of the lens
properties or design characteristics that FDA has
identified as ‘‘clinically significant’’ * * * or to protect
against any of the concerns raised in the 1975 notice
declaring as new drugs all contact lenses consisting
of polymers other than PMMA °* * *?

e. Should any reclassification take effect (i) before
or (ii) after such a standard has been established?

3. With respect to the lenses proposed for reclassi-
fication, FDA has limited data on their use for the
correction of hyperopia and in some cases aphakia.
May FDA reclassify a lens for use in the correction
of myopia, hyperopia, and aphakia based solely or
primarily on data showing that the lens is safe and
effective (a) for the correction of myopia? (b) for the
correction of myopia and aphakia?

4. Does specifying the materials of which the lenses
proposed for reclassification are principally composed
adequately identify the lenses for the purpose of re-
classification?

5. * * *, [T]he safety or effectiveness of a specific
rigid gas permeable contact lens is affected by its
specific composition, design, and various other clini-
cally significant properties.

33a

a. Do the data presented in this proposal provide
sufficient ‘‘valid scientific evidence’’ of the safety and
effectiveness of CAB or polyacrylate-silicone lenses
of any specific composition, design, or other charac-
teristic?

b. If the data do not provide this evidence, may the
identified lenses be reclassified because of FDA’s ten-
tative decision that the safety and effectiveness of
composition, design, or other clinically significant
properties of specific lenses can be assured through
premarket notification submissions and substantial
equivalence determinations?

7. - 7

B. Insufficient Evidence of Safety and Effectiveness

In response to question 1 above, a number of comments
presented cogent arguments that the data described in the
preamble to the proposal do not constitute sufficient new,
publicly available. valid scientific evidence (valid scientific
evidence) of safety and effectiveness to support reclassifi-
cation. FDA agrees in general with these comments, which
are discussed in detail in section ITI.C. of this document.
Additional comments in response to question 1.a. and in
response to the April 15, 1983 notice reopening the com-
ment period. in an effort to supply the valid scientific
evidence of safetv and effectiveness required for reclassi-
fication. submitted detailed summaries of a portion of clini-
cal trials conducted on two specific polyacrylate-silicone
contact lenses, and a detailed summary of the preclinical
evaluation of one of the lenses. (No data pertaining to the
safety or effectiveness of cellulose acetate butyrate (CAB)
rigid gas permeable lenses were provided in or submitted
with any comments.) As discussed in paragraph 14 of this
document. serious questions have been raised concerning
the completeness of the submitted data. Even if there were
no such auestions, however, the data merely would serve
to show the safety and effectiveness of two polyacrylate-

34a

silicone lenses characterized only by brand name and made
of unspecified material. Such a showing would be insuffi-
cient to justify reclassification because, among other things,
the information would fail to establish the safety and effec-
tiveness of polyacrylate-silicone lenses as a generic type
of device.

C. Inadequate Characterization of Materials

CAB or polyacrylate-silicone materials that might be
used for manufacturing rigid gas permeable lenses can
consist of thousands of formulations and have a wide vari-
ty of physical and chemical properties. Only a small per-
centage of such materials have the necessary combination
of characteristics of nontoxicity, biocompatibility, light
transmission, and machinability to serve as the basis for
the design and manufacture of safe and effective contact
lenses. Comments from opponents of reclassification argue,
and a comment from one proponent of reclassification
agrees, that minor changes in lens material formulation or
manufacturing process can significantly affect the safety
and effectiveness of lenses manufactured from the material.
A comment opposing reclassification further argues that
although controlled minor changes in a single variable by
a manufacturer can result in predictable changes in safety
and effectiveness, major or multiple changes, or a change
from one manufacturer to another. can result in changes
in the lens’ clinical performance that are not easily pre-
dicted.

FDA agrees with the comments opposing reclassification.
If specific CAB or polyacrylate-silicone lenses had been
shown to be safe and effective by valid scientific evidence
and had been characterized by polymer formulation and
manufacturing processes, such information might have been
sufficient to have allowed comparison, for the purpose of
determining substantive equivalence, with other lenses that
had been shown to be very similar in polymer formulation
and manufacturing process, and, as a result, to have al-

35a

lowed an inference of comparable safety and e*fectiveness
of such other lenses. However, no information about poly-
mer formulation and no information about manufacturing
processes was disclosed in or submitted with any of the
comments, and FDA is prohibited by sections 301(j) and
520(c) of the act (21 U.S.C. 331(j) and 360j(c)) from dis-
closing such information from PMA’s or files for investi-
gational devices under development pursuant to an investi-
gational device exemption (IDE) because such information
constitutes trade secret data. Lacking information about
polymer formulation and manufacturing processes, it is
not possible to compare one rigid gas permeable lens to
another for the purpose of determining substantial equiva-
lence; individual CAB and polyacrylate-silicone lenses are
snfficiently different from one another that the fact that
they are made from CAB or polyacrylate-silicone does not
allow an inference of comparable safety and effectiveness.

In summary, clinical evidence of the safety and effective-
ness of a limited number of individual lenses. characterized
only by general family of material, i.e. CAB or polvacryl-
a‘e-silicone, brand name, and manufacturer, would be in-
sufficient to serve as a basis for reclassification of a generic
type of device.

D. Inadequacy of Class { or Class [I to Provide Reasonable
Assurance of Safety and Effectiveness

Two comments from proponents of reclassification argue
in response to questions 1.b. and 5.b. above that the safety
and effectiveness of polyacrylate-silicone lenses, as identi-
fied in a definition offered by both comments, can be evalu-
ated against a group of parameters with assigned accept-
ance limits that are proposed in these comments as criteria
for the determination of substantial equivalence after the
reclassification of such lenses into class I. These parameters
include certain physical, optical, chemical, toxicological,
end biocompatib'lity criteria, but exclude clinical evalua-
tion. The comments argue that lenses that met the assigned

36a

limits for the parameters would be safe and effective,
which would negate the need for clinical trials as well as
the need for identification of the lenses with detailed in-
formation on polymer formulation and manufacturing
processes. The comments accordingly argue that the ab-
sence of information concerning formulation and process-
ing is not a bar to reclassification. The comments further
argue that use of these parameters would allow FDA to
determine substantial equivalence of new lenses to reclassi-
fied lenses and would ensure the adequacy of FDA review
of premarket notification submissions to screen out unsafe
or ineffective lenses. Other comments argue that to estab-
lish such parameters as criteria for determining substantial
equivalence to a class I device would be de facto imposition
of a performance standard. These comments urge the
agency to use such parameters as the basis for the develop-
ment of a performance standard under section 514 of the
act, and to reclassify the lenses into class IT.

To suffice as a basis for reclassification into class I or
class II, such a group of parameters, whether used to
determine substantial equivalence or as the basis for a
performance standard, would of necessity have to be shown
capable of providing reasonable assurance of safety and
effectiveness of the lenses bv valid scientific evidence. No
comments contained, and FDA is unaware of, any evidence
that if a lens met these parameters, there would be reason-
able assurance that the lens was safe and effective, or in
the event of reclassification, that the lens would be sub-
stantially equivalent in terms of safety and effectiveness
to any lens that had been reclassified. The absence of the
requisite evidence precludes using the parameters offered
by the comments as a basis for reclassification of rigid gas
permeable lenses into class I or class II.

E. Need for Clinical Trials

Several comments argue that the results of nonclinical
laboratory studies cannot be used to predict the clinical

37a

performance of a contact lens. Other comments argue that
the clinical performance of a contact lens can be readily
predicted from nonclinical laboratory studies.

None of the comments submitted any data to support
their arguments. FDA is unaware of any combination of
nonclinical laboratory studies capable of predicting the
clinical performance of any contact lens on the human eve.
Such studies serve well to screen out materials that should
not go on to clinical trials. For example, in vitro or animal
toxicity tests of a material or a material extract may
reveal an overt cytotoxic effect to an undifferentiated cell
line (the correlation of this effect to an ocular response
in humans has not been established) or gross systemic or
ocular toxicity. These tests are presumptive in nature and
serve at best to provide reasonable assurance that subjects
in a clinical trial would not be placed at undue risk from
exposure to a new or modified material used to make a
contact lens. However, nonclinical laboratory studies cannot
provide any data on human ocular biocompatibility, or on
adequacy of design (e.g., weight, thickness, geometry, cen-
tration). comfort, stability, durability, fit, and visual acuity,
nor can the results of such studies be used as the sole basis
from which to predict the clinical performance of an ap-
proved contact lens for which approval for a new indica-
tion is sought.

FDA believes that the safety and effectiveness of a
contact lens is a function of the complex interrelationship
of material. design, and manufacture that results in a
unique set of physical, chemical, mechanical, and optical
characteristics. When prescribed and fitted properly. a
lens with this unique set of characteristics should provide
safe and effective visual correction in a human eye with a
specific diagnosed ametropia. FDA believes that contact
lenses made from a new material, including material that
has been significantly modified, contact lenses made to
significantly modified designs, and contact lenses for which

38a

approval for a new indication is sought, cannot at this
time be shown to be safe and effective without clinical, as
well as preclinical, evaluation.

F. Conclusion

FDA has carefully reviewed and analyzed all the com-
ments received as well as the oral and written testimony
presented at the public hearing and has further reviewed
the data discussed in the preamble to the proposed rule.
On the basis of all this information, FDA has concluded,
contrary to the tentative conclusions stated in the proposal,
that there is insufficient valid scientific evidence to show
that the rigid gas permeable lenses proposed for reclassi-
fication are safe and effective, to characterize the device
adequately for the purpose of reclassification, or to demon-
strate that either class I or class IIT would provide reason-
able assurance of the safety and effectiveness of the device.
Class ITI is still necessary to provide reasonable assurance
of the safety and effectiveness of rigid gas permeable
lenses. .

This document withdraws FDA’s first proposal to re-
classify a device under section 513(e) of the act. The
agency initiated this proceeding because it tentatively con-
cluded that the new, publicly available, valid scientific evi-
dence of safety and effectiveness it had gathered was suffi-
cient to show that rigid gas permeable lenses shculd not
remain in class III and that class I would provide reason-
able assurance of the safety and effectiveness of the lenses.
However, as shown by the specific issues raised in the pre-
amble to the proposed rule (47 FR 53410), the April 15,
1983 notice reopening the record, and the agency’s decision
to hold a public hearing on the proceeding (see 48 FR
18836), FDA was concerned about the sufficiency of the
evidence it relied on in the proposal, and promulgation of
a final rule reclassifying the lenses was far from certain.
In response to the notice-and-comment procedures man-

39a

dated by the act and the regulations, as well as the public
hearing on the proposal, FDA received comments and oral
and written testimony that required it to reevaluate the
evidence upon which it relied in the proposal, and to evalu-
ate additional information presented by interested persons.
As a result of its evaluation and reevaluation of all the
_ information in the record of this proceeding, FDA learned
that the safety and effectiveness data summarized in the
preamble to the proposal were seriously deficient in many
respects, that lenses made of CAB or polyacrylate-silicone
are the products of complex polymer formulation and
manufacturing processes, that the information it would
have to require in a premarket notification submission to
determine whether a new lens is substantially equivalent
to a reclassified lens would exceed the authority of section
510(k) of the act and Subpart E of Part 807 of the regu-
Istions governing premarket notification procedures (?1
CFR Part 807, Subpart E), and that there is not sufficient
valid scientific evidence to develop a performance standard
under section 514 of the act to provide reasonable assur-
ance of the safety and effectiveness of rigid gas permeable
lenses. In short, FDA learned that at this stage in their
development, there is no substitute for clinical tria!s to
provide reasonable assurance of the safety and effective-
ness of these lenses.

If. ANALYSIS OF COMMENTS

The agency received appreximaieiy 200 comments on the
proposal, including written and oral testimony presented
at the May 26, 1983 public hearing. Comments were re-
ceived from manufacturers of contact lenses and contact
lens materials, optical latoratories, clinical investigators
of contact lenses, industry associations. members of Con-
gress, and other interested persons. The following is a
summary of the significan: comments received and FDA’s
responses to them.

40u

A. Classification

1. One comment suggests that rigid gas permeable lenses
are not class ITI devices under section 520(1)(1)(E) of the
act. According to the comment, the notice published in the
FEDERAL REGISTER of September 30, 1975 (40 FR
44844), which declared as new drugs contact lenses con-
sisting of polymers other than polymethylmethacrylate
(PMMA), was principally concerned with hydroxyethyl-
methacrylate (HEMA) contact lenses and was grounded
on incorrect information as to the composition of then
marketed PMMA lenses. The comment points out that then
marketed PMMA lenses did not consist ‘‘entirely’’ of
PMMA, citing the preamble to the proposed rule (47 FR
53404). The comment then argues that if the September
30, 1975 notice, which included a proposed rule to codify
the agency’s position, had not been withdrawn by a notice
published in the FEDERAL REGISTER of January 13,
1978 (43 FR 1966), literal application of the September 30,
1975 notice would have required FDA to regulate all con-
tact lenses as new drugs before enactment of the amend-
ments. The comment also argues that the September 30,
1975 notice, as allegedly interpreted by a notice published
in the FEDERAL REGISTER of December 16, 1977 (42
FR 63472) (the transitional notice) and the January 13,
1978 notice, applies only to HEMA (soft) lenses, and that
rigid gas permeable lenses are more closely related to
PMMA lenses than to soft lenses.

FDA disagrees with the comment. The term ‘‘soft’’ as
used in reference to contact lenses in the September 30,
1975 notice, the transitional notice, and the January 13,
1978 notice encompasses ail lenses other than those made
of PMMA. That one or more of these notices used the term
‘‘soft contact lenses’’ as a synonym for ‘‘non-PMMA
lenses’’ thus has no bearing on the classification of lenses
consisting of polymers other than PMMA. Furthermore,
the September 30, 1975 notice, which made it plain that

sd 8 eet dh

4la

FDA had in the past regarded, and would continue to
regard, as new drugs, contact lenses consisting of polymers
other than PMMA, expressly cited CAB, polycarbonate,
and silicone as examples of such other polymers (40 FR
44845). The notice, which advised that the agency had
taken this position since the 1960’s, accordingly applies to
rigid gas permeable as well as soft lenses.

As a result of the September 30, 1975 declaration, under
section 520(1)(1)(E) and (1)(3)(D)(i) of the act, non-
PMMA contact lenses on the date of enactment of the
amendments (the enactment date) were automatically
classified into class III without need for regulations or
other action on the part of the agency. The transitional
notice and the January 13, 1978 notice, which withdrew the
1975 proposed rule but did not affect its declaration, simply
provided interested persons further notice that non-PMMA
lenses were class III devices subject to the premarket ap-
proval requirements of section 515 of the act (21 U.S.C.
360e).

Although the September 30, 1975 notice stated that FDA
had in the past regarded, and would continue to regard,
contact lenses consisting ‘‘entirely of PMMA’”’ as dvvices,
the notice stated: ‘‘[t]he Agency has undertaken a study
to determine the extent to which adjuvants such as cross-
linking agents, resin bases, catalysts, colorants. and anti-
oxidants are used in the manufacture of contact lenses
consisting of PMMA to determine the effects of such ad-
juvants on the essential physicochemical characteristics of
PMMA and thus to determine which of these contact lenses
may be regarded as devices and which should be regarded
as new drugs’’ (40 FR 44845). The September 30, 1975
notice thus recognized that then marketed PMMA lenses
did not consist ‘‘entirely’’ of PMMA, and ‘“‘literal appli-
cation’’ of the notice would not have required FDA to
regulate all contact lenses as new drugs before enactment
of the amendments.

42a

FDA acknowledges that rigid gas permeable lenses are
more closely related te PMMA lenses than to soft lenses.
However, the components of rigid gas permeable lenses,
e.g., CAB, silicone acrylate monomers, and derivatives of
acrylate monomers, are not adjuvants. For this reason, as
well as by the express terms of the September 30, 1975
notice, rigid gas permeable lenses are not PMMA lenses
within the meaning of that notice.

FDA advises that any CAB lens for which a new drug
application (NDA) was filed and no order of approval or
refusal to approve had been issued on the enactment date,
e.g., MESO Contact Lens, is a class III device under sec-
tion 520(1)(1)(B) of the act; that any CAB lens for which
a notice of claimed investigational exemption for a new
drug (IND) was in effect on the enactment date, e.g.,
MESO Contact Lens, CABCURVE® Contact Lens, is a
class III device under section 520(1)(1)(C) of the act;
and that any CAB lens that is substantially equivalent to
a CAB lens covered by section 520(1)(1)(B) or (C) is a
class III device under section 520(1)(1)(D) of the act.

FDA advises that any polyacrylate-silicone lens for
which an IND was in effect on the enactment date, e.g.,
POLYCON®, is a class III device under section 520(1)
(1)(C) of the act and that any polyacrylate-silicone lens
that is substantially equivalent to a polyacrylate-silicone
lens covered by section 520(1)(1)(C) of the act is a class
IIT device under section 520(1)(1)(D) of the act.

B. Identification

2. One comment argues that CAB and polyacrylate-
silicone lenses constitute a generic type of device having
essentially the same characteristics and that, under 4 860.-
120(b) of the regulations governing reclassification, any
reclassification should extend to all devices fallimg within
that generic type. The comment recommends that proposed
) 886.5360 (21 CFR 886.5360) be amended to provide a

43a

generic description of the device by eliminating the limita-
tion to lenses in commercial distribution. Another comment
argues that the proposed rule, which the comment charac-
terizes as based on the composition of the device and its
status as a contact lens subject to approved NDA’s or
PMA’s, is unsound as a matter of policy and violates sec-
tion 520(c) of the act. The comment points out that FDA,
in the preamble to the proposed rule to classify ophthalmic
devices, stated: ‘‘[i]t is not practical for FDA to publish
an identification of each type of device that is so detailed
as to anticipate every product feature that may be relevant
in determining whether a new device is substantially equiv-
alent to previous devices classified by regulation. * * * ’’
(47 FR 3695; January 26, 1982). The comment claims that
classification must reflect the potential risk of illness or
injury and the need for varying levels of controls associ-
ated with the type or category of device rather than the
specific device, and states that this focus on the type or
category of device and the risks associated with such type
or category has been FDA’s previous approach to classifi-
cation of all ophthalmic devices under the act and is re-
quired by the act. For these reasons, the comment requests
that FDA withdraw proposed § 886.5360 and, if reclassifi-
cation is deemed warranted, propose a classification of the
category or type of device identified as ‘‘contact lenses.’’

FDA agrees that the identification paragraph of any
classification regulation should provide a generic descrip-
tion of the device. As explained in sections II.B. and C.
and paragraphs 13, 23, and 24 of this document, however,
the lens proposed for reclassification—a daily wear spheri-
cal lens consisting of CAB or polyacrylate silicone—has
not been adequately characterized for the purpose of re-
classification. Accordingly, identification of the generic type
of device as ‘‘the contact lens,’’ or even ‘‘the rigid gas
permeable lens,’’ even broader identifications than included
in the proposal, could not be adequate for that purpose.
FDA notes that if the proposed rule had been revised and

44a

promulgated to identify the generic type of device as ‘‘the
rigid gas permeable lens,’’ or as ‘‘the contact lens,’’ and a
manufacturer had submitted a premarket notification seek-
ing to market a new lens, FDA, to determine whether the
new lens was substantially equivalent to any lens in the
generic type, still would have compared the new lens to
lenses already covered by the final rule (see § 807.87(f) and
(h) of the regulations governing premarket notification
procedures).

FDA disagrees that identifying a device based on its
composition or regulatory status violates the letter or the
spirit of the act or the regulations issued under it. So long
as there is sufficient valid scientific evidence showing (1)
why a device should not remain in its present classification
and (2) that a change in its classification will provide rea-
sonable assurance of the safety and effectiveness of the
device, nothing in section 520(c) of the act or any other
section of the act, or in any of the regulations implement-
ing any section of the act, precludes identifying the device
by composition and previous status under section 505 (21
U.S.C. 355) or 515 of the act. FDA notes that the proposed
rule to classify ophthalmic devices includes a proposal to
classify into class II a device, namely, the PMMA contact
lens, identified in part by composition (47 FR 3736).

C. Adequacy and Safety and Effectiveness Data

3. Several comments state that rigid gas permeable
lenses may not be reclassified into a class other than class
III unless there is adequate valid scientific evidence of
safety and effectiveness to support reclassification.

FDA agrees with these comments (see the preamble to
the proposed rule (47 FR 53404) and section I.A. of this
document). Lacking adequate valid scientific evidence that
rigid gas permeable lenses are safe and effective, and that
class I would be sufficient to provide reasonable assurance
of the safety and effectiveness of such lenses, FDA may
not reclassify them from class ITI into class I or class II.

«

45a

4. One comment states that the burden of proof that
reclassification is appropriate is on FDA and on those who
support reclassification, regardless of whether those oppos-
ing reclassification can or do submit evidence showing that
reclassification is not appropriate.

FDA agrees with this comment. The legal standard for
reclassification is set out in the preamble to the proposed
rule (47 FR 53404) and in section IT.A. of this document.
FDA addressed the question of burden of proof in the
April 15, 1983 notice reopening the comment period (48
FR 16293) :

FDA recognizes that to reclassify the contact lenses
at issue in this rulemaking from class III into class I,
it must have new, publicly available, valid scientific
evidence of safety and effectiveness demonstrating why
the lenses should not remain in class III and why the
‘*general controls’’ authorized by the act will provide
reasonable assurance of the safety and effectiveness
of the lenses. * * * Although this notice requests spe-
cific evidence showing why the lenses should not be
reclassified, as well as evidence showing why they
should be reclassified, FDA has not shifted the burden
of proof to those opposing reclassification.

5. Several comments argue that the evidence needed to
reclassify a contact lens is at least equal to that which
would be necessary to meet FDA’s guideline concerning
testing of contact lenses, ‘‘FDA Contact Lens Guidelines
on Toxicology, Microbiology, Clinical Manufacturing Evalu-
ation and Controls’’ (Ref. 5 of the proposal) (the contact
lens guideline), and that FDA may not reclassify a lens
proposed for reclassification unless the valid scientific
evidence of the safety and effectiveness of that lens meets
the criteria of the guideline.

FDA guidelines state procedures or standards of general
applicability that are not legal requirements but are accept-

46a

able to FDA for a subject matter which falls within the
laws administered by the Commissioner (21 CFR 10.90(b)).
Conformance to the contact lens guideline accordingly is
not a legal prerequisite for premarket approval. It follows
that conformance to the guideline is not a lega! prerequisite
for reclassification of contact lenses. The evidence of safety
and effectiveness of the contact lenses proposed for reclassi-
fication has been evaluated by FDA against the criteria
for valid scientific evidence specified in § 860.7 of the regu-
lations.

FDA believes that the evidence needed to show that a
rigid gas permeable lens is safe and effective for the pur-
pose of reclassification is similar, but not necessarily iden-
tical to, the evidence suggested in the contact lens guide-
line to show safety and effectiveness for premarket ap-
proval. For example, for the purpose of reclassification,
comprehensive clinical data combined with detailed infor-
mation on polymer formulation and manufacturing pro-
cesses might obviate the need for the detailed reporting of
preclinical testing suggested in the guideline.

6. Several comments refer to FDA’s statement in the
preamble to the proposed rule that the safety of rigid gas
permeable lenses is shown by the absence of reports in the
literature of serious, irreversible adverse effects on health
presented by the device, and the absence of such reports
in FDA’s Device Experience Network (DEN). The com-
ments argue that rather than serving as evidence for re-
classification of the device, the lack of evidence of such
adverse effects is evidence of the success of the present
class III classification in assuring that only safe and effec-
tive lenses are marketed. The comments further argue that
extrapolation from the safety record of approved devices
to that of future deregulated devices is inappropriate.

The comments do not accurately restate the preamble,
which cited the absence of reports in the literature as one
item of evidence of the safety of rigid gas permeable lenses

47a

and simply noted that no serious, irreversible adverse
effects on health presented by the device had been reported
to DEN (47 FR 53405). FDA agrees, however, that the
safety record of rigid gas permeable lenses to date repre-
sents the performance of lenses for which there are ap-
proved PMA’s. The agency acknowledges that DEN is not
comprehensive and advises that the mere absence of nega-
tive reports in this voluntary reporting system cannot
establish the safety of a device. Before a device may be
reclassified under section 513(e) of the act from class IIT
into class I or class II, the act and the regulations require
that the safety, as well as the effectiveness, of the device
be established by valid scientific evidence.

7. A few comments suggest that FDA has not conducted
an adequate search for evidence of serious or permanent
injury from contact lens wear. One comment provided
copies of published articles dealing with complications
caused by certain silicone elastomer lenses marketed in
Germany and Japan; other comments provided bibliogra-
phies of published articles dealing with injuries allegedly
related to contact lens wear.

Before issuing the proposed rule, FDA searched dili-
gently for evidence of serious, irreversible adverse effects
presented by each of the lenses proposed for reclassification
when used in accordance with its labeling and under proper
professional supervision, and found no such evidence.
Since then, FDA has reviewed articles cited in the com-
ments as containing evidence of such effects. This latest
review confirms FDA’s earlier findings. Injuries to the eve
related to use of approved contact lenses invariably are
traceable to factors associated with improper lens use,
care, or fitting. While such reports of injuries argue force-
fully for the need for continued diligence in the regulation
of contact lenses, they do not preclude reclassification if
there is adequate, valid scientific evidence of the safety and
effectiveness of the devices when used and fitted properly.

48a

The silicone elastomer lenses associated with the re-
ported complications in wearers of the lens in Germany
and Japan were not, as admitted in the comment, of the
type proposed for reclassification, and by definition would
require premarket approval before being marketed in the
United States.

8. One comment argues that safety and effectiveness data
for contact lenses having different clinically significant
properties and design characteristics cannot be pooled to
show the safety and effectiveness of all lenses consisting of
CAB or all lenses consisting of polyacrylate-silicone. The
comment states that there are thousands of formulations
of CAB which vary from one another in such significant
characteristics as toxicity and dimensional stability. The
comment concludes that generally accepted scientific meth-
ods for use of test results would dictate that data for
lenses with differing safety and effectiveness parameters
not be pooled.

FDA agrees with this comment. Data on the polymer
formulation and manufacturing processes for the different
approved CAB lenses are not publicly available. Unless
the CAB lenses are shown to be identical by such data, the
agency may only assume that each CAB lens has different
safety and effectiveness parameters from other such lenses.
In addition, pooling of the clinical safety and effectiveness
data on which the proposed rule was based would be in-
appropriate because of the deficiencies in the data (see
paragraphs 10 through 12 of this document). There is in
the record no information identifying by polymer formula-
tion, manufacturing process, and related parameters any
of the rigid gas permeable lenses proposed for reclassifica-
tion. Absent such information, the safety and effectiveness
of one rigid gas permeable lens cannot be compared with
the safety and effectiveness of another rigid gas permeable
lens. This lack of characterizing data precludes pooling
of data from clinical investigations.

49a

9. In response to question 3 in the preamble to the pro-
posed rule, two comments argue that any reclassification
of rigid gas permeable lenses should include indications
for the correction of hyperopia and aphakia as well as
myopia because there appears to be no basis upon which
to limit to specifie refractive corrections the significance
of the data presented in the preamble. Five comments argue
on the contrary that data showing that a lens is safe and
effective for myopia cannot be used to support the safety
and effectiveness of the lens for the correction of byperopia
and aphakia. These comments state that lenses indicated
for the correction of hyperopia and aphakia are of neces-
sity significantly different in design and geometry from
lenses indicated for the correction of myopia. These com-
ments also state that lenses for the correction of hyperopia
and aphakia generally require an increased lens center
thickness compared to lenses for the correction of myopia.
Increased lens center thickness results in a reduction in
the oxygen permeability of the lens and concomitant safety
and effectiveness concerns unique to these lenses, accord-
ing to the comments. Therefore, the comments opposing
reclassification conclude that only clinical trials can pro-
vide reasonable assurance of safety and effectiveness of a
contact lens indicated for the correction of hyperopia or
aphakia.

Because FDA is withdrawing the proposed rule, the
question whether FDA may reclassify rigid gas permeable
lenses for myopia, hyperopia, and aphakia based solely or
primarily on data showing that the device is safe and
effective for the correction of myopia, or myopia and
aphakia, is moot. FDA advises, however, that none of the
comments provide any evidence to support the contention
that reclassification of rigid gas permeable lenses indicated
for the ecrrection of myopia, hyperopia, and aphakia could
be based solely or primarily on data demonstrating that
the lenses are safe «.." effective for the correction of my-
opia or for the con «‘ion of myopia and aphakia.

50a

FDA agrees with the comments that argue that the lens
characteristics required to provide safe and effective cor-
rection of hyperopia or aphakia are significantly different
from the lens characteristics required to provide safe and
effective correction of myopia. However, lenses indicated
for the correction of hyperopia and aphakia may be identi-
cal in design and concomitant safety and effectiveness
characteristics where the range of magnification for the
two indications overlap. The aphakic eye is a worst case
for both safety and effectiveness considerations for a con-
tact lens because of physiological changes to the cornea
from the insult of surgery. Among other things, these
changes could result in alterations in corneal oxygen re-
quirements. Consequently, FDA advises that for lenses
identical in material, design, and magnification range, the
safety and effectiveness of a lens for the correction of
hyperopia may, in large measure, be inferred from evi-
dence of the safety and effectiveness of a lens for the
correction of aphakia. Similarly, if the safety and effec-
tiveness concerns that are unique to a lens intended for
the aphakic eye are adequately addressed by clinical trials
of the lens in aphakic eyes, the safety and effectiveness of
that lens may, in large measure, be inferred from evidence
of its safety and effectiveness for the correction of hyper-
opia. FDA advises, however, that it has not been demon-
strated by valid scientific evidence that the safety and
effectiveness of a lens for the correction of hyperopia can
be inferred solely from evidence of the safety and effective-
ness of a lens for the correction of aphakia, or that the
safety and effectiveness of a lens for the correction of
aphakia can be inferred solely from evidence of the safety
and effectiveness of a lens for the correction of hyperopia.

10. One comment generally criticizes the published arti-
cles (Refs. 22-27 (see 47 FR 53411)) relied on in the pre-
amble to the proposed rule as valid scientific evidence of
the safety and effectiveness of CAB lenses. The comment
states that the articles are deficient in that they do not

ee

Sla

consistently state clear objectives, that they do not have
an adequate method of subject selection, that they do not
include sufficient information to allow comparisons between
test and control groups, and that most of the articles are
based on retrospective clinical evaluation, and therefore
suffer from the bias of evaluating successful patients. The

ocular data, and implies that the number of patients studied
is inadequate.

FDA acknowledges that .the articles criticized by the
comment have some deficiencies in study protocols, in pa-
tient selection criteria, in the number of patients studied,
or in reporting of important clinical results. FDA notes
that no evidence of the safety or effectiveness of any CAB
lens was included in or submitted with any comment on
the proposed rule. Consequently, the deficiencies noted in
the comment and which, as discussed below, show that the
articles do not constitute valid scientific evidence of safety
and effectiveness, preclude reclassification of CAB lenses.

a. “‘A Clinical Study of CAB Lens Wear’’ by Kline and
DeLuca (Ref. 22). This study, which apparently was retro-
spective, reports on 100 myopic patients who could tolerate
an unidentified CAB lens on an initial visit. The investi-

study lens is safe and effective for daily wear.

b. “‘Clinical Experience with the Cabcurve Contact
Lens’’ by Sigband (Ref. 23). This study reports on 65 pa-
tients, including 54 myopes, 4 hyperopes, and 7 aphakes,
who were ‘‘contact lens failures.’ The study includes no
data on visnal acuity, except a table of summarizing best

52a

visual acuity achieved, and no data on any other evaluation
criterion. The study population, which included only 55
successful patients, is small. However, the question of size
is overshadowed by the absence of adequately reported
data on any significant evaluation criterion.

c. ‘‘Gas-Permeable Cellulose Acetate Butyrate (CAB)
Contact Lens’? by Hales (Ref. 24). This study, which ap-
parently is retrospective, reports on 50 patients who had
been unsuccessful wearers of hard contact lenses and who
were subsequently fitted with an unidentified CAB lens.
The study contains one chart of visual acuity with CAB
lenses as compared to visual acuity with hard lenses. No
other data are provided. The small retrospectively reviewed
patient population and the absence of data for any criterion
except visual acuity renders this study inadequate to deter-
mine the safety and effectiveness of the lens under study.

d. “‘Oxygen-Transmitting Hard Contact Lens’’ by Man-
dell (Ref. 25). This study alludes to an experiment in which
nine PMMA contact lens wearers were refitted with an un-
identified CAB lens to determine whether the change would
alleviate persistent edema associated with wearing the
PMMA lenses. No data are provided on any criterion ex-
cept edema. The study does not purport to establish the
safety and effectiveness of lenses made of CAB.

e. ‘Extended Wear of CAB Contact Lenses in Aphakic
Patients’’ by Garcia (Ref. 26). This study appears to be
a well-conducted study of continuous extended wear (for
1 to 6 weeks between removals for cleaning) of a CAB
lens for the treatment of aphakia. Patients were followed
for an average of 24 months. However, the study’s sum-
mary presentation of data does not allow scientific evalua-
tion of the safety and effectiveness of the lens for continu-
ous wear, or therefore, for daily wear. For example, the
report contains no visual acuity data or quantitative data
on edema, slit lamp findings, or epithelial staining, which
are all necessary to permit scientific evaluation of the

53a

safety and effectiveness of the lens. Because the study
“‘lack[s] sufficient details to permit scientific evalnation,’’
the study is ‘‘not regarded as valid scientific evidence to —
show safety or effectiveness’’ (21 CFR 860.7(c)(2)). The
study lenses were identified as the Rynco Scientific Corp.
Rx 56 Lens (used early in the study) and the Danker and
Wohik, Inc., Meso CAB lens (used late in the study).

f. ‘Corneal Response to Extended Wear of CAB Con-
tact Lenses in Aphakia’’ by Kaplan and Triber (Ref. 27).
The purpose of this study was to determine the effect of
extended wear of Danker Labs., Inc. MESO CAB lenses
on corneal thickness. The authors make no claim of estab-
lishing the safety or effectiveness of CAB lenses.

In conclusion, FDA agrees with the comment that Refs.
22-27 are inadequate to show the safety and effectiveness
of CAB lenses.

11. A few comments state that the two published articles
relied on in the preamble to the proposed rule (‘Clinical
Evaluation of the Polycon 8.5 Design’’ (Ref. 30) and ‘‘Pa-
tient Responses to Gas-Permeable Hard ( Polycon) Contact
Lenses’’ (Ref. 31); see 47 FR 53411) do not constitute
adequate valid scientific evidence of the safety and effec-
tiveness of the specific polyacrylate-silicone lens reported
on. Therefore, the comments argue that the articles cannot
constitute adequate valid scientific evidence of the safety
and effectiveness of all contact lenses made of polyacrylate-
silicone and proposed for reclassification. The comments
state that Ref. 30 defines success as the ability io wear the
lens for 10 hours per day, but includes no data from which
to determine either safety or effectiveness, i.e., there are
no data on epithelial staining, neovascularization, corneal
edema, change in keratometry readings, corneal thickness,
endothelial cell counts, or visual acuity before or after lens
wear. Further, the comments state that although Ref. 31
includes most of the data believed to be necessary to evalu-
ate a lens, it reports on only 46 patients and does not
indicate how long the patients in the study were followed.

d4a

FDA agrees with these comments. All the data referred
to by the comments are essential to any determination of
the safety and effectiveness of a contact lens. Ref. 30 con-
tains insufficient data to allow a scientific judgment of the
safety and effectiveness of the lens under study. Ref. 31,
with only 31 successful study patients and an indefinite
followup period, is insufficient to demonstrate the safety
and effectiveness of the lens under study because the study
population is too small to generalize in a meaningful way
and because no quantitative data are provided for any
significant evaluation criterion except edema. It necessarily
follows that because the data included in Refs. 30 and 31
do not provide sufficient valid scientific evidence of the
safety and effectiveness of the lenses studied by the in-
vestigators, Refs. 30 and 31 cannot establish the safety
and effectiveness of lenses not included in the studies.

12. A few comments, including a comment from the lens’
manufacturer, discuss Refs. 30 and 31 of the proposal and
state that the material used to make the lenses in these
studies, identified only as POLYCON®, has been repiaced
by an improved material, POLYCON II® and tinted
POLYCON II®. The comment from the manufacturer
points out that the two latter lenses were approved by
FDA only after preclinical and clinical studies following
FDA’s contact lens guideline demonstrated that lenses
made of the new materials were safe and effective. The
comment from the manufacturer further states that POLY-
CON® and POLYCON II® materials differ in polymer
constituent ratios with concomitant differences in oxygen
permeability and wettability, major factors in determining
safety and effectiveness. The comments argue that FDA
never would have approved the PMA for the POLYCON®
lens, much less the POLYCON II® lens, on the basis of the
data in the cited references. Consequently, the data cannot
be an adequate basis for reclassification of the general
category of polyacrylate-silicone lenses.

55a

FDA agrees with these comments. FDA required com-
plete nonclinical laboratory studies and clinical investiga-
tions for the POLYCON IT® and tinted POLYCON II®
lenses because changes had been made in the polymer ratios
in the first case, and in certain polymer constituents in the
second case. The evidence of safety and effectiveness of
lenses of POLYCON® was therefore determined to be
inapplicabi: to POLYCON IT® and to tinted POLYCON
IT®. The data in the cited studies would not have been
adequate to support premarket approval of POLYCON®
and would have been considered inapplicable to POLYCON
IT®. It follows that the data in the cited studies are insuffi-
cient to show the safety and effectiveness of polyacrylate-
silicone lenses as a generic type of device for the purpose
of reclassification.

13. Six comments submitted data from clinical investiga-
tions of two different polyacrylate-silicone contact lenses,
the Paraperm 02™ and the Optacry] 60, covering a total of
approximately 1,100 patients. One of the comments also
included data from the laboratory testing (preclinical
evaluation) of the Optacryl 60 lens. The comments argue
that these data, most of which were the same as the clinical
and preclinical data submitted in PMA’s for these lenses,
constitute ample valid scientific evidence of safety and
effectiveness to serve as the basis for reclassification of
rigid gas permeable lenses made of polyacrylate-silicone.
The comments further argue that similarity of favorable
resuits between the different varieties of polyacrylate-
silicone show that the polyacrylate-silicone lenses consti-
tute a generic type of device and that changes in polymer
ratios do not give rise to divergent clinical results.

FDA disagrees with these comments. Questions concern-
ing the completeness of the submitted data are discussed
in paragraph 14 of this document. Those questions aside,
none of the comments contains polymer formulation or
manufacturing processes or any other information that

56a

would allow characterization of the lenses studied, and as
explained in sections II.B. and C. and paragraphs 23 and
24 of this document, evidence of the safety and effective-
ness of a specific polyacrylate-silicone lens cannot be gener-
alized to another polyacrylate-silicone lens without such
information.

Taken at face value the data submitted with these com-
ments support the conclusion that the lenses designated as
the Paraperm 0:™ and Optacryl 60 are safe and effective.
However, because the polymer ratios of the two lenses were
not identified in the comments, conclusions pertaining to
the effect on safety and effectiveness of differences in poly-
mer ratios cannot be drawn. The assumption that the poly-
mer ratios of Paraperm 0:™ and Optacryl 60 are different
only allows the conclusion that polyacrylate-silicone lenses
of more than one polymer ratio may be found to be safe
and effective. It does not logically follow that changes in
polymer ratios do not give rise to divergent clinical results.

Changes in the ratio of the principal ingredients of
polyacrylate-silicone polymers, as illustrated by the follow-
ing table, adapted from a table in a U-S. Patent for a poly-
acrylate-silicone lens material (Ref. 1), can be expected to
result in significant changes in the oxygen permeability of
lenses made from the ingredients listed in the table. Differ-
ences in oxygen permeability of the magnitude shown on
the chart can be expected to give rise to divergent clinical
results that significantly affect safety and effectiveness
(Refs. 1 and 2).

57a

Composition
SIGMA EGMA EDMA MMA Oxygen permeability (Dk)
parts mL.cm./om.*sec.cm.Hg
30 5 5 60 30X10"
40 7 5 48 62X10
50 9 5 36 114X110"
60 ll 5 24 184 xX id
70 13 5 12 25.5 X 10°
80 10 5 5 318 xX 10°

NOTE: ,

EGMA: Ethylene glycol monomethacrylate

EDMA: Ethylene glycol dimethacrylate

MMA: Methyl methacrylate

SIGMA is identified in the text of the patent as:
Methyldi-(trimethylsiloxy) sylylpropylglycerol methacrylate.

Oxygen permeability (Dk) is expressed as the product of the
diffusion coefficient for O02 movement in the material (D) and the
solubility constant for O; in the material (k).

14. Two comments question whether the safety and effec-
tiveness data submitted with other comments on the Para-
perm O:™ and Optacryl 60 contact lenses constitute valid
scientific evidence of the safety and effectiveness of these
lenses. The comments point out that the data submitted
cover approximately 1,100 subjects whereas the studies in-
cluded more than 100,000 subjects. The comments question
the basis for selection of the subjects included in the sub-
mitted data, whether the selection process biased the re-

58a

sults of the studies, what the incidence was of adverse
reaction in the total study population, and what efforts
FDA has made to establish that these data do not repre-
sent a select subject population or group. The comments
argue that if these questions are open, the data cannot be
considered to be valid scientific evidence of safety and
effectiveness.

In general, absent information about effectiveness and
the incidence of adverse reactions in a total study popula-
tion, and how the data submitted were selected from those
available, FDA cannot determine whether the submitted
data show, by valid scientific evidence, that an investiga-
tional device is safe and effective (see, e.g., § 860.7(f) (1)
(ii) and (v)). In any event, because the lenses in the clini-
cal investigations are only identified by general family of
material, i.e., polyacrylate-silicone, brand name, and manu-
facturer, and no information is provided to characterize
them by polymer formulation or manufacturing processes,
the data do not and cannot show the safety and effective-
ness of polyacrylate-silicone lenses as a generic type of
device for the purpose of reclassification (see sections II.B.
and C. and paragraphs 13, 23, and 24 of this document).

15. Two comments state that the cata from the clinical
investigations of the Paraperm 0:™ and the data from
nonclinical laboratory studies and clinical investigations
of the Optacryl 60 polyacrylate-silicone rigid gas perme-
able lenses, discussed in paragraphs 13 and 14 of this docu-
ment, have been reviewed by the Ophthalmic Device Sec-
tion of the Ophthaimic; Ear, Nose, and Throat; and Dental
Devices Panel (the Section), an FDA advisory committee,
during the Section’s review of PMA’s for the subject
lenses. The comments argue that because the Section rec-
ommended approval of the PMA’s for the Paraperm 02™
lens and the Optacryl 60 lens, the data constitute valid
scientific evidence within the meaning of § 860.7(c).

59a

The question whether the data constitute valid scientific
evidence of the safety and effectiveness of the studied
lenses is discussed in paragraph 14 of this document. FDA
advises that during the Section’s review of the PMA’s,
the Section did not consider all the issues relevant to re-
classification, e.g., the adequacy of the characterization of
the devices or the adequacy of class I or class II to provide
reasonable assurance of the safety and effectiveness of the
devices. In any event, a PMA approval recommendation
from an advisory committee simply is a recommendation
and is not a determination by FDA that data in the PMA
constitute valid scientific evidence.

16. More than 100 comments were received from pro-
fessionals in the contact lens industry who regularly pre-
scribe, fill prescriptions for, and fit contact lenses. More
than 80 of these comments were from persons who identi-
fied themselves as investigators of polyacrylate-silicone
contact lenses. As defined in § 812.3(i) of the regulations
providing procedures for the conduct of clinical investi-
gations of devices (the IDE regulations) (21 CFR 812.3
(i)), an investigator is an individual who gathers safety
and effectiveness data for a sponsor who intends’ to seek
premarket approval for a device. Each of the more than
100 comments favors reclassification of polyacrylate-sili-
cone lenses from class IIT into class I.

FDA responds to these comments in paragraphs 17 to
21 of this document.

17. The comments from investigators argue that the
data gathered as a result of the investigators’ studies and
similar investigations provide more than ample valid scien-
tifie evidence of the safety and effectiveness of polyacryl-
ate-silicone contact lenses. Some investigators, including
one investigator who studied 1,100 polyacrylate-silicone
lenses, one who studied 3,000 polyacrylate-silicone lenses,
and one who studied 7,000 polyacrylate-silicone lenses, cite
the number of lenses studied.

60a

FDA disagrees with these comments, the number of
lenses investigated notwithstanding. FDA is prohibited by
section 520(c) of the act from using as the basis for the
reclassification of a device trade secret or confidential
commercial information obtained under section 520(g) of
the act (exemption for devices for investigational use).
Consequently, except for those trade secret and confidential
commercial data from clinical investigations that were made
public in other comments and that are discussed elsewhere
in this document, such data gathered by investigators are
not available to FDA for the purpose of reclassification.

18. As evidence of safety, more than 30 investigators
state that in their use of polyacrylate-silicone contact
lenses, they have observed no adverse reactions.

Statements by individual investigators that no adverse
reactions were found do not constitute valid scientific evi-
dence within the meaning of § 860.7 of the regulations.
Section 860.7(c)(2) states in part ‘‘* * * reports lacking
sufficient details to permit scientific evaluation * * * are
not regarded as valid scientific evidence to show safety or
effectiveness.’’ To meet the test of valid scientific evidence
and permit scientific evaluation such reports need to in-
clude, at a minimum, a uniform scientifically acceptable
definition of adverse reaction, the number of patients
studied, and comprehensive summaries of the results of
examinations for edema and staining as well as slit lamp
examinations, and of all reports of discomfort, blurred
vision, and of patients who discontinued use of the lenses
or were otherwise lost to followup.

19. Several comments from investigators argue that
when all other things are equal, the polyacrylate-silicone
lenses that have been subjected to clinical investigations
are superior to PMMA lenses because the former have
been shown to be gas permeable and, thus, provide better
oxygenization of the cornea. These comments state that
this increase in oxygenization results in reduced edema

6la

and greater wearer comfort, and allows the lens to be
tolerated by the wearer for a longer period of time than
PMMA lenses. There are no significant differences in the
machining (lathing, grinding, and polishing) characteris-
tices of the two materials, according to the comments.
Therefore, the comments argue that any lens that can be
made of PMMA also can be made of polyacrylate-silicone.
Consequently, polyacrylate-silicone lenses should not be
classified into a higher class than lenses made of PMMA,
which FDA has proposed to classify into class IT.

FDA disagrees with these comments. The classification
of contact lenses made of PMMA is not legally relevant
to the classification of rigid gas permeable lenses. As dis-
cussed in the September 30, 1975 notice (40 FR 44845),
contact lenses made of PMMA have been marketed in the
United States since the early 1950’s. Due to their extensive
history of safe and effective human use, PMMA lenses
were regulated as devices prior to the enactment of the
amendments and thus never required administrative ap-
proval for marketing. In contrast, rigid gas permeable
lenses were first marketed in the United States in the
late 1970’s and always have required premarket approval.
Indeed, since the introduction of hydrophilic (soft) contact
lenses in the 1960’s, FDA has regarded all contact lenses
other than those made of PMMA as new drugs requiring
premarketing clearance (see paragraph 1 of this document).
The September 30, 1975 notice explains that the agency’s
decision to require such clearance for all contact lenses
made from non-PMMA materials ‘‘ * * * was based on a
recognition that new plastic materials that had not been
shown to be safe and effective [for use] were being intro-
duced for use in the manufacture of contact lenses. The
introduction of these new materials led to new lens design
and use, new manufacturing methods, and new methods
for lens care. [FDA] is concerned that the use of these
contact lenses may result in serious eye damage if the
new material of which they are composed is unsafe for

62a

use in the eye, if the user cannot feusibly care for the
lenses, or if the highly complex procedures for the manu-
facture of these lenses are not carefully controlled to assure
a product of uniform quality’’ (40 FR 44845).

As explained in paragraph 1 of this document, rigid gas
permeable lenses were automatically classified into class
ITI on the enactment date of the amendments in accord-
ance with section 520(1)(1)(B), (C), and (E) of the act.
Such lenses may only be reclassified into class I or class II
in accordance with the provisions of the act and the regu-
lations as discussed in the preamble to the proposed rvle
(47 FR 53404) and in section IT.A. of this dormment.

Neither the safety nor the effectiveness of pol,acrylate-
silicone lenses has been established by valid scientific evi-
dence other than in PMA’s. Furthermore, FDA is not
aware of, and no comments provided, evidence that there
are no significant differences in the machining characteris-
tics of PMMA and any of the formulations of polyacrylate-
silicone used to manufacture any of the investigational
lenses about which comments were submitted. On the con-
trary, one comment from an investigator cites machining
differences, including increased tool wear, longer polishing
times, and reduced yield for polyacrylate-silicone compared
to PMMA. FDA believes that these differences reflect po-
tential significant differences in the characteristics of
PMMA and polyacrylate-silicone lenses, for example, sur-
face finish and uniformity.

20. Ten comments from investigators note that approved
lenses are routinely modified in optical laboratories to
improve the fit for specific patients. The potential superior
fit of custom fitted lenses is cited as an advantage of the
investigational lenses over approved lenses, and as an
argument for reclassification. Custom fitted lenses, specifi-
eally the polyacrylate-silicone lenses under investigation
by those submitting comments, result, according to the
comments, in a better fit and concomitant better comfort

_ ie ot a

and tolerance for those patients whose eyes do not pre-
cisely match the dimensions of approved lenses. Approved
polyacrylate-silicone lenses are only available in a limited
number of configurations, according to the comments.
Therefore, the comments argue that custom fitted investi-
gational polyacrylate-slicone lenses allow successful fitting
of a larger portion of the potential lens wearing population
than is currently possible with approved polyacrylate-
silicone lenses. Custom fitted lenses also are said to allow
a more perfect fit for those patients for whom the best fit
of an approved lens is a compromise.

FDA acknowledges that some portion of the user popu-
lation cannot always be fitted successfully from a fixed set
of lenses, and that some of these individuals might be fitted
successfully through modification of off-the-shelf lenses.
FDA notes that nothing in the act or the regulations for-
bids optical laboratories from modifying approved lenses
to meet the needs of specific patients so long as the specifi-
cations of the lenses, as modified, remain within the specifi-
cations of the PMA’s for the approved lenses. For this
reason, there is no basis for the argument that investiga-
tional lenses are subject to ‘‘eustom fitting,’’ while ap-
proved lenses are not. Further, the comments appear to
presuppose that the investigational lenses in question have
been shown to be safe and effective in the first place; the
comments do not add to the bo

[Text truncated at 120,000 characters. The full text is on the page linked above.]

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/brief%3Amicro_IA40385018_1180%3A2. Public record. Not legal advice.
